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Christchurch Hospital has implemented EPIgray, an EPID based in-vivo dosimetry (IVD) sys-
tem for dosimetric verification of treatment. The current EPIgray clinical tolerance of ±5% has
been set for all sites treated using 3D conformal radiation therapy (3DCRT). This project aims
to optimise the use of EPIgray for treatment verification of 3DCRT breast treatments, by estab-
lishing a site specific clinical tolerance, reducing false positive results and investigating causes
of error.
Methods
A retrospective study was performed in which 30 previously treated 3DCRT breast patients
were re-analysed within EPIgray with the current tolerance. EPID based IVD systems are
susceptible to setup errors on treatment. Positional corrections in EPIgray were performed
to identify groups of patients at increased risk of having setup errors on treatment, and the
impact of these on the EPIgray result. For controlled tests to validate the findings of the ret-
rospective study, a phantom representing breast and lung tissue was designed. The phantom
was positioned for treatment with setup errors of known magnitude in all orthogonal planes to
compare EPIgray reconstructed doses against other routinely used dosimeters. An uncertain-
ties investigation was also conducted in which the uncertainties associated with the EPIgray
reconstructed doses were determined specifically for the treatment parameters used for 3DCRT
breast treatments.
Results
The retrospective study has revealed that right breast patients and large breast patients were
more prone to setup errors than left breast patients and small breast patients. The phantom
study revealed that EPIgray reported doses are in agreement with the delivered dose. Whilst
the accuracy of EPIgray was determined to be systematically offset from other dosimeters, the
results have indicated that EPIgray can be reliably used with appropriate tolerances. The re-
sults of the uncertainties investigation have shown that the intervention clinical tolerance for
3DCRT breast treatments can be reduced to ±3.5% with the aim of detecting potential treat-
ment errors whilst still accounting for inherent uncertainties associated with EPIgray and the
uncertainties associated with the variations in treatment.
Conclusions
This project has clinically validated the use of EPIgray for treatment verification of 3DCRT
breast treatments. A new intervention tolerance of ±3.5% was recommended for all 3DCRT
breast patients. This tolerance is smaller than the current intervention tolerance of ±5.0% and
would aid in the reduction of false results.
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1 Introduction
1.1 Breast Cancer Overview
Cancer is the uncontrolled growth and spread of abnormal cells [1]. Ordinarily, normal cell
behaviour such as cell division, specialisation and death are under the control of signals from
the homeostatic system. Abnormal cancer cells however do not obey these signals. Cancer
cells therefore increase in size and number, persisting at the expense of the organism without
any given benefits. The presence of cancer cells interferes with normal cell function ultimately
leading to illness and death.
Recent data published by the World Health Organisation (WHO) has shown breast cancer to
be the most common form of cancer in women in New Zealand (Figure 1.1) and worldwide
(Figure 1.2). Figures 1.1 and 1.2 also identify breast cancer to be one of the leading causes
of cancer-related death in women. Cancer trends published by the Ministry of Health New
Zealand (MoHNZ) reveal that more people in New Zealand are now developing cancer, largely
as a result of an ageing population [2]. WHO predicts that by 2040, the incidence of breast can-
cer in New Zealand will increase by 30% from the 2018 incidence rates [3]. However, whilst the
prevalence of breast cancer is considered to be high, the burden of cancer can be dramatically
reduced through early detection and appropriate treatment.
Surgery, chemotherapy and radiation therapy are the most common treatments for breast can-
cer. Each treatment option has associated advantages and disadvantages that are extensively
discussed in literature [4]. It is reported that over 50% of all cancer patients may benefit from
radiation therapy in the management of cancer [5]. While lumpectomy and mastectomy are ef-
fective surgical procedures for treatment of breast cancer where the tumour or the entire breast
is respectively removed, an abundance of research reveals that the local recurrence of breast
cancer can be dramatically decreased with adjuvant radiotherapy [6], [7].
2 Chapter 1. Introduction
FIGURE 1.1: Estimated number of incident cases and deaths in women in New Zealand [3]
FIGURE 1.2: Estimated number of incident cases and deaths in women worldwide [3]
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1.2 Radiotherapy for Treatment of Breast Cancer
Radiation therapy for cancer treatments involves the use of radiation to kill cancer cells. The
foundation of radiotherapy relies on the interaction between high energy ionising radiation
and the molecules that make up the deoxyribonucleic acid (DNA) of a cell [8]. Cell DNA con-
tains information associated with the cell division, growth and development. Therefore the
interactions that occur between the ionising radiation and the cell DNA causes disruption to
the cell function, ultimately leading to cell death [9].
Numerous radiotherapy techniques such as brachytherapy, intra-operative radiotherapy and
external beam radiation therapy (EBRT) are employed for the treatment of breast cancer [10].
EBRT is the most common form of radiotherapy treatment for breast cancer. In EBRT, the radi-
ation is externally produced and is focused on the tumour as opposed to placing a radioactive
source within the tumour [11]. The radiation for modern EBRT techniques are typically gener-
ated by a linear accelerator (linac), shown in Figure 1.3.
FIGURE 1.3: Linear accelerator at Christchurch Hospital
The radiation produced for EBRT treatments must travel from an external source to the treat-
ment site. Radiation does not selectively affect cancer cells and therefore radiation interactions
with healthy cells will also result in the damage or death of normal cells which may lead to
detrimental consequences for the patient [12]. The ultimate aim of radiotherapy is to accu-
rately deliver the prescribed dose to the tumour volume whilst minimising the dose to the
surrounding healthy tissue.
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Radiotherapy treatments are administered by prescribing a radiation dose to a specific treat-
ment volume. The absorbed radiation dose is defined as the mean energy imparted by ionising
radiation per unit mass. The absorbed dose has units of Gray (Gy), where 1 Gy is equivalent
to 1 J kg−1. Complete avoidance of healthy tissue irradiation cannot always be achieved. As
such, fractionation of radiotherapy treatments was introduced to increase eradication of cancer
cells whilst sparing normal tissue through repair of sublethal damage. Fractionation of the to-
tal prescribed dose refers to a treatment scheme in which the total prescribed dose is delivered
in smaller doses over multiple treatment sessions. For example 30 Gy total dose is delivered to
the patient in 2 Gy over 15 treatment sessions (fractions). The basis of fractionation is explained
by the four Rs of radiotherapy [13]:
1. Repair: The time between fractions allows normal cells to repair sublethal damage.
2. Repopulation: The time between fractions allows for repopulation of normal cells.
3. Redistribution: The time between fractions redistributes the cancer cells to radiosensitive
cell cycle phase to increase cell killing when exposed to radiation.
4. Reoxygenation: The time between fractions allows reoxygenation of the tumour volume,
which subsequently increases the radiosensitivity of the cell [14].
During breast cancer EBRT treatments other normal cells and organs at risk (OAR) such as the
heart and lungs may receive an unnecessary radiation dose. Consequently, measures are taken
in the planning and execution stages of the radiotherapy treatment to decrease the dose to the
normal cells and organs at risk.
1.2.1 EBRT Radiotherapy Treatment Process
The steps of the radiotherapy treatment process are schematically shown in Figure 1.4. Follow-
ing diagnosis and decision to treat, the patient will have a consultation appointment with the
radiation oncologist to receive information regarding their radiotherapy treatment. Following
patient consent, the patient will undergo a series of preparative processes to be able to deliver
the radiation treatment accurately [15].
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FIGURE 1.4: Flow diagram of the radiotherapy treatment process
Firstly, the computed tomography (CT) simulation takes place, in which CT images are ac-
quired of the patient in their expected treatment position. The patient is set up using a range
of immobilisation devices customised to their body for two reasons. The first is to ensure that
the patient is in a reproducible treatment position for all fractions of their treatment. Slight dif-
ferences in patient positioning from intended position could lead to a full or partial geometric
miss of the tumour volume giving rise to a lack of local tumour control and additional increase
in the risk of normal tissue complications. Secondly, immobilisation devices are also employed
to allow better access to the treatment site, whilst providing a comfortable position for the pa-
tient. For example, immobilisation devices are used to support the patient’s arms when they
are asked to hold their arms above their heads for treatment of breast cancer. By placing arms
above their head, the arms will receive comparatively lower dose than if the arms were placed
directly adjacent to the breasts.
In addition to customisation of immobilisation devices, the patient will also receive small tat-
toos (often called skin reference points), where the external lasers in the CT room are incident
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upon their skin. On treatment, the patient will be set up in their treatment position using
identical immobilisation devices. The external lasers in the treatment bunker and the patient
reference tattoos are used to setup the patient in a near identical position to their setup at the CT
simulation. It is important to maintain the same patient position from simulation CT through
every fraction of the treatment as the simulation CT scans will be used in the treatment plan-
ning process.
Images from these CT scans allow the treatments to be specifically tailored to each patient.
The simulation CT images that were acquired are imported into the treatment planning system
(TPS). The TPS is used to contour the relevant anatomical structures. Delineation of these struc-
tures not only allow effective beam placement during treatment planning but also allows for
calculation of doses to these structures. The Hounsfield Units associated with the CT images are
converted to electron densities within the TPS. The TPS uses a dose calculation algorithm and
combines patient anatomical information from the CT with the physical radiation processes
that are expected to occur as the radiation interacts with the tissues that it traverses through to
provide the dose distribution within the patient.
The treatment plan is then evaluated and approved for treatment. Treatment plans are evalu-
ated with reference to the dose constraints for normal tissue and treatment volume to ensure
that there is minimal normal tissue complication whilst maintaining an appropriate level of
tumour control. Following evaluation and acceptance of the plan, an independent check is per-
formed on the plan to identify any errors in the treatment planning process and data transfer to
the linac console. If necessary, plan-specific quality assurance (QA) is performed to assess the
dosimetric accuracy of the plan. QA in radiotherapy is defined as “all procedures that ensure
consistency of the medical prescription, and safe fulfilment of that prescription, as regards to
the dose to the target volume, together with minimal dose to normal tissue. . . and adequate
patient monitoring aimed at determining the end result of the treatment” [16]. QA in radiother-
apy serves to detect errors and prevent the corresponding consequences early in the treatment
process. Additionally QA may minimise the uncertainties associated with each stage of the
radiotherapy process to better improve the overall accuracy of radiotherapy treatments.
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Following evaluation of plan safety and acceptance of the plan, the patient treatment can begin.
The reference tattoos and lasers are used to approximately position the patient on treatment
to be the same as at CT simulation. Pre-treatment imaging is then performed to verify the
position of the treatment volume and OAR before the treatment commences. Pre-treatment
imaging involves acquisition of verification images on treatment and comparing these images
to the images from CT simulation to ensure that the patient is in the correct treatment position.
Further shifts of the patient on treatment are performed as required. Once the patient position
on treatment is verified, the treatment is delivered to the patient.
Safety in Radiotherapy
Over time radiotherapy has become a highly complex process as a result of advancing research
and improving technology. The professional expertise required to execute such treatments is
rapidly on the rise. The complexity of modern radiotherapy is mainly attributed to the numer-
ous steps involved in the planning and delivery processes of these treatments [17]. Increasing
complexity of these treatments has led to an increase in the number of errors that could arise
which may compromise the treatment intent. Ford et al. identified 127 possible failure modes,
starting from the decision to treat with radiotherapy to ultimately delivering the dose to the
patient [17].
An error in radiotherapy is defined as “a non-conformance where there is an unintended di-
vergence between a radiotherapy treatment delivered or a radiotherapy process followed and
that defined as correct by local protocol” [18]. Error in radiotherapy may occur in any one of
the steps involved in the treatment process. While the consequences of the errors may vary in
severity, precautions must be taken to avoid errors at each and every step to ensure the most
accurate treatment possible. Unintended adverse effects following radiotherapy may be in-
dicative of clinically significant error in radiotherapy. The risk of a clinically significant error
in radiotherapy was estimated to be 3 per 100,000 courses of treatment [19]. Although the risk
is considered to be small, complacency is not an option because the consequences could be fatal.
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1.3 Treatment Verification
Modern radiotherapy is continuously evolving in order to more effectively concentrate the dose
to the tumour volume. With increasing complexity, the treatment plans become less intuitive
and more reliant on the algorithms employed by the TPS. While using the TPS is beneficial
in avoiding human errors in dose calculations, the associated decrease in human input into
the treatment plan may give rise to other errors. While pre-treatment QA procedures min-
imise errors and uncertainties with reference to the dose delivery, in more complex treatments,
pre-treatment QA procedures are not sufficient at identifying radiotherapy errors. Treatment
verification consequently became an important aspect of radiotherapy treatments.
Treatment verification is defined as the “process by which the accuracy of radiotherapy is as-
sessed" [18]. Treatment verification as part of QA is relatively new in comparison to the exis-
tence of radiotherapy treatments. However, treatment verification is increasingly being used
and is widely recommended by various international bodies including WHO, the International
Commission on Radiological Protection (ICRP) and the International Atomic Energy Agency
(IAEA) [20]. The doses predicted by the TPS in comparison to the doses delivered to the pa-
tient during treatment are subject to minor and major variations. Various factors ranging from
minor setup errors to major treatment errors can lead to differences in the dose delivered to the
patient.
Although not required by legislation in New Zealand, in-vivo dosimetry (IVD) is now increas-
ingly being recommended by the MoHNZ to ensure treatments are executed as expected [21].
IVD refers to the measurement of the dose delivered to the patient during treatment delivery.
IVD is therefore the most direct method of verifying that the correct dose has been delivered to
the patient. Because radiotherapy treatments are typically fractionated, performing treatment
verification early in the treatment serves as an additional safe guard against major dosimet-
ric errors that may have gone unnoticed until the consequences of incorrect treatment become
apparent. IVD entails the use of a radiation dose detector (dosimeter) to provide an indica-
tion of the dose delivered to the patient. The dose indicated by the dosimeter is subsequently
compared to the dose calculated by the TPS to provide an indication of the accuracy of the
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treatment delivered.
1.3.1 In-Vivo Dosimeters
There are many types of IVD dosimeters in clinical use. A summary of the dosimeters used in
this study and the corresponding advantages and disadvantages are outlined below.
Ionisation Chambers
Ionisation chambers (IC) are gas filled volumes with polarising electrodes (anode and cathode)
as shown in Figure 1.5. Radiation interaction with the gas volume inside the chamber results
in the formation of positive and negative ions. The polarity of the electrodes attracts the ions
of the opposite charge. The magnitude of the charge collected is subsequently correlated to
the number of radiation interactions that have occurred. Consequently, the radiation dose to a
particular point can be inferred.
FIGURE 1.5: Simple diagram of a farmer type ionisation chamber [14]
Literature has shown that an IC of an appropriate volume will provide an accurate measure-
ment of dose. As such, IC are clinically used for determination of dose to water which are
subsequently used for dose calculations. Other advantages of IC include good long-term sta-
bility, reproducibility, linear response to dose, small angular dependence and immediate read-
out. IC are also often used in patient specific QA procedures in which the IC is inserted into
a phantom (representing the patient) to measure the absolute dose to a point. This measured
dose is then compared to the TPS dose to check for consistency between the treatment plan and
treatment delivery. While IC has a range of applications in radiation oncology, IC are typically
unsuitable for most IVD applications because of the required polarising voltage and difficulty
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in positioning the IC at a clinically relevant position. Furthermore the positioning of the IC is
also important because any offset will introduce uncertainties to the point dose measurements
[22].
Radiochromic Film
Radiochromic film is a widely adopted dosimeter in radiation oncology departments. Ra-
diochromic film have one or two thin radiosensitive layers. The radiosensitive layers consists
of microcrystals of a monomer dispersed in a gelatinous binder. The radiosensitive layers un-
dergo polymerisation when irradiated with ionising radiation. The polymerisation causes the
radiochromic film to change optical density as a function of dose. The opacity of the film is
then correlated to the dose deposited to the film.
Radiochromic film have many features that ensure its use in radiotherapy as a dosimeter. Major
advantages of the radiochromic film are the near tissue equivalency of the sensitive layer and
decreased sensitivity to light in comparison to radiographic film. Additionally, radiochromic
film do not require chemicals to process, and they provide information on the two-dimensional
(2D) dose distributions. While radiochromic film have many associated advantages, they are
also relatively expensive, require scanning equipment to determine the dose delivered and
have strict readout protocols. Additionally dosimetric analysis using radiochromic film is time
consuming and cannot be performed in real time [22].
Electronic Portal Imaging Device
Electronic portal imaging devices (EPIDs) were first invented to replace film in radiotherapy
and were designed for positional verification of patients on treatment, where the treated area
could be reviewed post treatment. EPIDs are typically employed for transit dosimetry in which
a patient or a phantom is placed in the beam between the source and the EPID. Figure 1.6a
shows an acquisition of a transmission EPID image of a patient using a built-in EPID on a
linac. The linac gantry is rotated around the patient to deliver treatment from various gantry
angles. The linac gantry and the EPID always oppose each other and therefore EPID images
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can be acquired at any gantry angle. The EPID positioned on the other side of the patient reg-
isters the x-rays that have been attenuated by the patient as a 2D image [23].
(a)
(b)
FIGURE 1.6: EPID on a linac (a) Patient transmission EPID image acquisition setup [24]
(b) Perkin Elmer aSi EPID [25]
The most commonly used EPIDs are amorphous silicon (aSi) EPIDs. Figure 1.6b shows the
construction of the EPID panel used in this study. The major components an aSi EPID are the
scintillator plate, aSi photodiode array and electronics for reading out the image formed. The
interaction between the radiation and the scintillator material, Gd2O2S:Tb results in the con-
version of radiation to light. The light produced is then detected by an array of photodiodes
that are implanted in the aSi. The photodiodes then integrate the light into charge captures and
are registered as values for that pixel. Therefore the signal formed is dependent on the amount
of charge captured per unit pixel of the imaging panel. The image captured on the EPID is pro-
portional to the amount of transmission through the patient or the phantom. The values can
consequently be used to infer the level of attenuation that has occurred as a result of having an
attenuating medium in the path of the beam. The aSi EPID used in this study has a resolution
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of 1024 x 1024 16-bit pixel images and an effective detector size of 26 x 26 cm at the isocentre 1.
EPID images are used for positional verification by comparison to the digitally reconstructed
radiograph (DRR) simulated by the TPS.
The use of EPIDs in EBRT radiotherapy treatment verification is rapidly increasing because of
their many advantages including its ability to provide high resolution images and an instant
readout [20]. Additionally EPID images can be saved as a permanent electronic copy for record
keeping. Furthermore, the use of EPID in EBRT for positional verification can be achieved
without additional radiation dose to the patient because most modern linacs already have a
built-in EPID and therefore images can be acquired during the treatment beam. Additionally,
the images acquired using an EPID also allows the determination of dose to a point within
the patient/phantom, given that the oncology department possesses a dose calculation algo-
rithm for calculating dose using EPID images. Due to its many advantages, EPIDs have been
highly researched in order to implement their use for positional and dosimetric verification in
radiotherapy treatments [22].
1.3.2 Literature Review: Current Use of EPID-Based IVD
The use of EPIDs for positional verification is common at most radiotherapy centres how-
ever EPID based dosimetric verification is still relatively new. Numerous publications have
addressed different aspects of EPIDs for use in dosimetry. Boyer et al. provided a detailed
overview of the historical perspective that lead to the technological development of the EPID
[27]. More recently Antonuk [28], and Kirby and Glendinning have also published the techno-
logical advancements in EPID technology to the current state [29].
The prospect of using EPID for dosimetric analysis and treatment verification has been under
rapid development because the image acquisition using an EPID is efficient, of high resolution
and is acquired in a digital format with capability of use in IVD. Consequently, the dosimetric
and physical properties of aSi EPID have been studied by several groups [23]. Figure 1.7 shows
the rapid increase in interest through journal publications relating to EPID dosimetry.
1In radiation oncology, the isocenter is a point in space through which the central rays of the radiation beam pass
through [26].
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FIGURE 1.7: Number of publications relating to EPID dosimetry [23]
Point-Dose Verification
The ability to determine the dose to a point of interest has historically been shown to be useful
in identifying clinically significant, systematic errors that are likely to recur in each successive
fraction [30]. The initial motivation for point-dose verification based on EPID transmission im-
ages arose to eliminate diodes in IVD. Diode measurements are performed by placing a diode
either at the entrance or the exit surface of the patient [31]. The diode would need to be cali-
brated to measure the dose at a specified point within the patient. However, the use of diodes
for IVD entails set up time on treatment as well as additional time associated with the accurate
calibration of the device. Additionally diodes also affect the treatment by attenuating the beam.
EPIDs can overcome these issues [23].
Comparisons of transmission based point dose measurements have been performed at various
positions. These include comparisons of measurements made at the plane of the EPID [32],
back projected to a point of interest within the patient (variable in depth) or a generic point
within the patient, e.g. 5 cm depth ([33], [34]) or at the isocentre ([35]–[38]). These publications
reveal that the accuracy of the reconstructed doses, regardless of the position at which the doses
are calculated is strongly dependent upon two factors. The first is the dose reconstruction
algorithm, and the second is the treatment site.
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Errors Detected Using EPID Dosimetry
Elmpt et al. have identified a number of errors that are clinically detectable using EPID dosime-
try. These errors were categorised as treatment related or patient related errors. Publications
have shown that both systematic and random errors associated with the treatment can be iden-
tified using EPID dosimetry. Treatment related errors include unexpected variations in the
treatments parameters and linac radiation output. These errors are detectable using EPID due
to the differences in the dose distribution measured using an EPID and the dose distribution
provided by the TPS. The ability to detect these errors in earlier fractions will prevent major
dosimetric errors and consequently will be clinically beneficial [23].
Patient related errors particularly errors that occur as a result of patient positioning on treat-
ment or changes in patient anatomy from the planning stages of the treatment are also iden-
tifiable using EPID dosimetry. Regardless of which category these errors fall into, the EPID
dosimetry measurements made during the first fraction of the treatment are capable of alert-
ing treatment staff to errors that have the capacity to cause drastic changes to the expected
treatment outcome. Therefore EPID treatment images that are acquired during treatment with
no added setup time or dose to the patient, serve as an additional check and a record of the
accuracy of the treatment [23].
Breast Treatment IVD Using EPID
Numerous publications have addressed the use of point-dose treatment verification for vari-
ous sites using EPID dosimetry [33]–[38]. Ricketts et al. evaluated a transit dosimetry protocol
and assessed the issues in the clinical implementation of EPIDs for IVD treatment verification.
Ricketts et al. studied a number of treatment sites including breast, prostate, tonsil, tongue, and
larynx and found that the magnitude of dose difference between the planned and the delivered
treatment is dependent on the treatment site. Their study concluded that an optimisation of the
dose calculation for different treatment sites and groups of patients would be an advantageous
possibility [39].
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Celi et al. more specifically examined the use of EPIgray. EPIgray (DOSIsoft, France) is a dose
reconstruction software for IVD which uses the EPID images acquired on treatment to recon-
struct a dose to a point of interest within the patient. Celi et al. found that the EPIgray re-
constructed doses of breast treatments in comparison to other sites more often showed greater
dose deviations from the TPS planned doses. Root cause analysis was subsequently performed
across all their patients to study the cause of these deviations. Celi et al. have found that
the EPIgray dose reconstruction is often performed over an incorrect environment as a conse-
quence of variations in patient and EPID positioning on treatment. Celi et al.’s findings regard-
ing the misalignment of the patient and EPID positioning has resulted in DOSIsoft developing
algorithms for automatic image repositioning to accurately represent treatment conditions for
the dose reconstructions [40]. Literature research has revealed that currently there is a lack of
information regarding the optimisation of EPIgray for different treatment sites. Additionally,
Celi et al. have identified the need for site specific optimisation of the EPIgray software for
reliable use. This project aims to optimise the use of EPIgray for 3DCRT breast treatments.
1.4 EPIgray
EPIgray utilises the information contained in the transmission EPID images of the patient in
their treatment position to reconstruct a dose to a point of interest within the patient. The inten-
sity values associated with the pixels of the grey scale image is associated with a dose through
the use of a calibration factor. The calibration factor is determined during EPID calibrations in
which a known dose is delivered to the EPID and the resulting grey scale values of that image
are correlated to the dose delivered. Using the transmission EPID image, EPIgray employs a
back-projection dose calculation algorithm described by Francois et al. to reconstruct the dose
a point of interest [41]. Francois et al.’s formalism employs a dose reconstruction approach in
which the dose at the EPID plane is back-projected to a point of interest within the patient. The
steps of the formalism are outlined below.
1. The dose measured on the EPID is converted to dose to water.
2. The dose to water from the previous step is converted to dose to water without an atten-
uator (patient or phantom) in the way of the beam.
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3. The inverse square law (ISL) is then employed to calculate the dose to the point of interest
(within the patient or phantom).
4. The final dose to the point of interest is then calculated by combining the dose from the
previous step with the scatter contribution from the attenuator.
The EPIgray reconstructed dose is used to provide the percentage dose difference (%DD) be-
tween the TPS planned dose and the delivered dose calculated by EPIgray at the point of inter-






DEPIgray is the dose calculated by EPIgray
DTPS is the dose planned on the TPS
1.4.1 EPIgray for EPID-Based IVD at Christchurch Hospital
EPIgray is an independent analysis system. Therefore EPIgray can be used for error detection
in both dose delivery and patient positioning. EPIgray only requires an EPID image that was
acquired during treatment and the initial plan data. Therefore most modern linacs with a built-
in EPID can obtain the benefit of treatment verification following each fraction. Additionally,
setup time associated with a lot of other in-vivo dosimeters currently in use can be avoided.
Currently at Christchurch Hospital, curative-intent 3DCRT patients with limited low density
tissue in the treatment field will have EPID images acquired on treatment for treatment veri-
fication using EPIgray. A tolerance of ±5.0% has been set between the planned dose and the
EPIgray reconstructed dose based on commissioning data. This baseline tolerance was set to
account for the inherent uncertainties associated with EPIgray and other treatment-related un-
certainties. The current tolerance is a generic tolerance and is department specific. The current
tolerance gives rise to false positive results, where false positives results are dosimetric results
that appear to be within ±5.0% but are not truly within the ±5.0% tolerance. False positives
occur as a consequence of a range of reasons including but not limited to: variations in patient
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positioning, incorrect acquisition of EPID image acquisitions and/or dosimetric errors. False
positive results limit the reliable use of EPIgray for treatment verification of 3DCRT breast pa-
tients because there are chances that the EPIgray provided %DD is not representative of the
dose delivered to the patient. At Christchurch Hospital the use of EPIgray is restricted to pa-
tients with limited low density tissue in the treatment field as EPIgray is known to perform
poorly for accurate dose calculations involving widely varying tissue densities [39]. The use of
EPIgray for IVD has tremendous potential however, clinical experience and literature review
have revealed that the optimisation of the software for specific treatment sites are necessary to
ensure efficient and reliable use [40].
1.4.2 EPIgray Workflow
EPIgray requires information from the TPS and the linac for dose calculation. The information
required by EPIgray from each of the inputs is described below. The EPIgray workflow is also
schematically shown in Figure 1.8.
FIGURE 1.8: Schematic representation of EPIgray workflow
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Exporting Information from TPS to EPIgray
EPIgray requires two inputs. The first is the treatment planning information that is exported
from the TPS and directly imported into EPIgray. The information from the TPS is sent prior
to treatment and includes the patient planning data in digital imaging and communications in
medicine (DICOM) format. The following components of the plan are required from the TPS
for EPIgray to be able to calculate the dose delivered to the patient:
• Patient CT image set.
• The radiation therapy plan with a marked point of interest at a known co-ordinate.
• The radiation therapy structure set, which includes details of the treatment volume as
well as the OAR.
• Planned doses including total doses per fraction as well as individual beam doses within
a fraction to the point of interest.
Exporting Information from the Linac to EPIgray
The EPID shown in Figure 1.9 will be extended throughout the treatment to acquire patient
transmission images during the treatment. Figure 1.9 shows EPID position relative to the linac
gantry. The EPID will oppose the linac gantry at every gantry angle to acquire transit EPID
images. A transmission EPID image is acquired for every beam of radiation (treatment field)
within the fraction. Once all the EPID images are acquired for a given fraction, these images
are manually imported into EPIgray in DICOM format.
FIGURE 1.9: EPID in extended position to acquire a patient transmission image when
the patient is set up on the treatment couch (black bed)
19
2 Aims of Research
The primary aim of this research is to optimise the use of EPIgray as an IVD system to improve
the safety of 3DCRT breast radiotherapy treatments. Currently, the allowed %DD between
TPS dose and the EPIgray calculated dose has been set to a tolerance of ±5.0%. For specific
categories of patients, it may be possible to reduce this tolerance when particular treatment
conditions such as treatment volume size or laterality (side of the body treated) are met. In op-
timising the information obtained from EPIgray regarding breast treatments, the intention is to:
Aim 1: Use EPIgray to identify specific groups of patients at increased risk of having posi-
tional offsets on treatment
One of the aims of this research is to identify patients who are more at risk of having larger
setup errors which may have the potential to compromise the treatment intent. As part of a
retrospective study, patients who have previously been treated at Christchurch Hospital will
be reanalysed within EPIgray. The relationship between the %DD between TPS and EPIgray
doses and patient related factors such as the size of the patient’s breast (target volume) and
laterality of treatment volume will be considered to identify specific factors that influence the
accuracy of the EPIgray calculated %DD.
Aim 2: Decrease the current tolerance between the TPS predicted dose and the EPIgray cal-
culated dose
The current EPIgray tolerance was set based on the results of the EPIgray commissioning tests.
This tolerance is not site specific and currently gives rise to false positive results in which the
EPIgray provided %DD appears to be within the tolerance however the true result is not. False
positive results may be decreased by decreasing the current tolerance with considerations to
factors that specifically affect 3DCRT breast treatments. In addressing this aim, the optimal
tolerance for 3DCRT breast treatments will be investigated and verified for clinical use with
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consideration of the potential impact of the new tolerance on the clinical resources.
Aim 3: Identify more optimal points in analysis of dose difference between TPS dose and
EPIgray dose
Currently the dose difference is considered for a user-specified point of interest. Other clin-
ically relevant points will also be considered in order to decrease the %DD tolerance. With
the most recent EPIgray update, 50 random points are generated within EPIgray. The doses to
these points are calculated and the average dose to that volume is given [42]. This aim strives
to identify whether the dose at the user-specified point of interest or the mean dose of 50 auto-
mated points provides the closest indication of the dose delivered to the patient on the day of
the treatment.
Aim 4: Verify the ability of EPIgray to detect discrepancies between TPS calculated dose
and the delivered dose
The entire EPID based IVD system will be tested using a phantom. The phantom will have
realistic anatomical dimensions and electron densities, with comparable geometry and het-
erogeneities to a patient. End-to-end tests will be performed in which the phantom will be
treated as a patient receiving 3DCRT breast treatment. The planned dose to the phantom and
the EPIgray calculated doses for setup errors of zero and known magnitudes will be used to
identify the agreement between the TPS doses and EPIgray doses.
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2.1 Study Outline
This section provides a brief overview of the chapters to follow. The study has been divided
into three parts:
I Retrospective study,
II Phantom study, and
III Uncertainty investigation
Chapter 3 addresses part I of this study. As part of the retrospective study, the effect of posi-
tional correction within EPIgray to account for setup errors on the %DD was examined. Previ-
ously treated patients with varying magnitude of setup errors on treatment were corrected for
within EPIgray. The %DD before and after the positional correction on EPIgray were analysed
for specific groups of patients. The retrospective study was designed to address research aims
one, two and three.
Chapter 4 addresses part II of this study. As part of the phantom study, a phantom was de-
signed to mimic breast and lung tissue for dosimetric measurements. The phantom study was
designed in order to validate the findings of the retrospective study. Additionally, the reliabil-
ity of the %DD between TPS and EPIgray doses was tested by comparing the %DD between
TPS and other established dosimeters. The phantom study chapter addresses research aim four.
Chapter 5 addresses the major factors contributing uncertainties to the EPIgray reconstructed
doses. In considering these factors, a new EPIgray tolerance has been proposed for 3DCRT
breast treatments. The clinical impact of imposing the recommended tolerance is also dis-
cussed in this chapter. Chapter 5 addresses the second research aim of this study.
Lastly, Chapter 6 discusses the major findings and the clinical impact of this study, as well as
the proposed future work of this project.
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3 Retrospective Study
This chapter will address the sensitivity of EPIgray to setup errors on treatment through a ret-
rospective study in which 30 previously treated 3DCRT breast patients were analysed using
EPIgray. This study was designed to use EPIgray to identify specific groups of patients at in-
creased risk of having setup errors on treatment. The findings of this study may be used to
help justify decreasing the current clinical tolerance of ±5.0% for specific groups of patients.
The retrospective study grouped patients according to treatment laterality and the size of breast
seen on the EPID images. Breast laterality was investigated due to the differences seen between
the left and right breast fields. Left breast fields may have the presence of the heart to consider
whilst the right breast fields will not. The effect of this difference was investigated in this study.
Breast size was also investigated as the size of the breast will directly impact the scatter condi-
tions and consequently the EPIgray reconstructed doses.
Following the import of all required information into EPIgray, an automatic back-projection cal-
culation provides the %DD to a point of interest. At Christchurch Hospital the point of interest
is the dosimetric reference point (DRP). The DRP location is user defined and must meet a set
criteria for sensible use. The International Commission on Radiation Units and Measurements
(ICRU) provides guidelines and criteria to determine an appropriate DRP. The DRP used at
Christchurch Hospital is based on the recommendations of the ICRU. ICRU recommends that
firstly the dose at the DRP must be representative of the treatment volume and be clinically rel-
evant. Secondly, the DRP must be situated at a point where there are no sharp dose gradients
and the dose can be accurately determined [43].
Ideally the %DD at the DRP (%DDDRP) is expected to be 0%, indicating that there is no differ-
ence between the planned dose and EPIgray calculated dose. However deviations are likely as
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a result of a number of reasons discussed in section 1.3.2 "Errors detected using EPID dosime-
try". While there are several factors that influence the %DD, previous publications have iden-
tified setup errors on treatment to be the main cause of deviation between the planned and
calculated doses [40]. The setup errors on treatment can be categorised into patient-related and
EPID-related errors.
Patient-related errors may be systematic or random. When considering setup errors, random
errors are always present in a radiotherapy setting. While the use of immobilisation devices
can minimise the setup errors, the treatment of the breast does involve movable tissue. Ad-
ditionally movement of the breast tissue is also likely with breathing motion. As such, the
slight differences in the placement of breast tissue relative to the treatment field will affect the
EPIgray calculated dose and consequently %DDDRP. In contrast, systematic errors are errors
of similar magnitude and are likely to persist at all fractions of the treatment. For example,
if the treatment staff have accidentally input incorrect numbers for patient setup, the patient
will be setup at a different treatment position from the expected treatment position at every
fraction. Consequently the dose received by the patient is different to the planned dose and the
patient will not have received the appropriate treatment. Both random and systematic errors
pose a great risk to the patient if these errors are large enough to compromise the treatment
intent. Consequently, these errors highlight the importance of having an IVD system in place
for identifying major set-up errors.
The study by Celi et al. identified EPID positioning on treatment to also have an impact on the
EPIgray reconstructed dose [40]. The EPID position must be correctly aligned with the patient
and the radiation source as expected by the TPS to provide the most accurate dose. However,
the treatment fields associated with breast treatments may be asymmetrical to provide shield-
ing to the nearby OAR such as the lungs. Therefore the EPID position may need to be shifted
from its initial deployed position to a more appropriate position for the entire transmission
image to be captured. Consequently the EPID position is different to the TPS expected position
and the reconstructed dose will reflect this change in the reconstruction environment. The pro-
vided dose and consequently the %DD does not indicate dosimetric errors, as the patient could
still be in the expected treatment position. Given that the patient has been set up accurately and
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the linac is within the expected operating parameters, the DRP within the patient should have
received the correct dose because the patient would have been setup relative to the radiation
source and not the position of the EPID. With changes to the expected EPID position, the pro-
vided %DDDRP would have been calculated by associating the EPID signal to the wrong plan
parameters. Therefore in cases where the EPID has been shifted, the position of the EPID must
be corrected for within EPIgray to ensure the %DDDRP is representative of the actual treatment
delivered to the patient. This concept is schematically shown in Figure 3.1.
(a) (b) (c)
FIGURE 3.1: Schematic illustration of positioning errors on EPIgray results. (a) Recon-
struction is expected to be performed at the yellow star, however setup errors have re-
sulted in the dose reconstruction to be performed in a different environment (orange
arrow). (b) Dose is reconstructed based on different plan parameters than expected and
is evident by the lack of agreement between the shape of the breast seen on the EPID
image and contours of the breast from the TPS (orange contour). (c) Manual alignment
of the EPID image to the TPS contours has been performed to ensure that EPIgray calcu-
lates a dose that is dependent on the true environment present at treatment.
Subsequent to this current work, in the most recent update of EPIgray, released on 14th De-
cember 2018 DOSIsoft enabled fractional dosimetric analysis using the reconstructed doses at
50 automatically generated points. After EPIgray has received all the information it requires
from the TPS, EPIgray randomly generates 50 points within a volume that is representative of
the treatment volume. EPIgray reconstructs the doses at these 50 points to provide a fractional
mean dose to the volume, a %DD to the volume (%DDvol) and the standard deviation associ-
ated with the reconstructed dose. DOSIsoft now recommends the use of the %DDvol rather than
department specified points e.g. the currently used DRP at Christchurch Hospital. The use of
%DDvol in the place of %DDDRP would be a significant change in practice at Christchurch Hos-
pital. The feasibility of the use of %DDvol in place of the currently used %DDDRP for indication
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of treatment delivery accuracy according to EPIgray was also investigated as part of this study.
3.1 Correction Methods
The EPIgray software allows the use of two methods to correct for patient and EPID positional
errors to obtain a %DDDRP that reflects the treatment delivered to the patient. These two meth-
ods are:
1. EPID position correction, and
2. Contour matching correction
3.1.1 Correction Method 1: EPID Position Correction
Manual adjustment of the EPID position within EPIgray allows correction of offset EPID po-
sition that has occurred on treatment. EPID position correction is performed by aligning the
planned field edges that are imported directly from the TPS to the edges of the EPID image
captured on treatment. Consequently the %DDDRP that is obtained following correction of the
EPID position is more indicative of the treatment delivered to the patient. Figure 3.2a shows
an example of a misalignment between the EPID image and the field edges imported from the
TPS. Following a manual adjustment of the EPID position within EPIgray, there is acceptable
alignment between the EPID image and the field edges as seen in Figure 3.2b.
(a) (b)
FIGURE 3.2: Effect of EPID position correction (a) Misalignment seen between the field
edges (purple rectangular box) and the EPID image. (b) EPID position correction per-
formed on EPIgray to align field edge to EPID image.
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3.1.2 Correction Methods 2: Contour Match Correction
The ability to position the patient in the exact position they were in during the simulation CT
is difficult to achieve. Immobilisation devices customised specifically for the patient will aid
in decreasing the variations in patient positioning on treatment. However, immobilisation de-
vices will not eliminate these variations altogether. Such variations in patient positioning can
be corrected for within EPIgray to provide a %DDDRP that is more reflective of the treatment
delivered to the patient.
Contour match correction can be performed within EPIgray by aligning the patient contour
evident on the EPID image to the patient contour from the TPS. An example of contour match
correction is shown in Figure 3.3. The green points in Figure 3.3 are points at which EPIgray
calculates the dose. These points are automatically and randomly selected by EPIgray. The
cyan asterisks seen in Figure 3.3 represents the DRP. The dose to be delivered to the patient in
3DCRT breast treatment is prescribed to the DRP when planning to provide uniform dose dis-
tribution to the entire breast volume. The DRP is user-specified within the TPS and the dose at
this point is known. The dose reconstructed at the DRP is used to provide %DDDRP calculated
using equation 1.1. By performing contour match correction, the DRP is effectively shifted
closer to the position where the TPS expects the DRP to be relative to the patient’s anatomy, i.e.
contour matching allows the DRP to be positioned in relation to the breast and lung tissue in-
stead of the field edges. Therefore contour match correction is arguably better at providing an
indication of treatment accuracy in comparison to EPID position correction because the former
method focuses on the tissue itself instead of the reconstruction field of view.
The main limitation of contour match correction is that if patient offset on treatment has oc-
curred, there will be a difference in the dose calculated to the DRP. However, not correcting for
patient offset on treatment will lead to an overestimation in dose to the DRP due to the lim-
itations associated with the EPIgray back-projection dose calculation algorithm. The impact




FIGURE 3.3: Effect of contour match correction (a) Misalignment seen between the plan-
ning breast contour (orange contour) and the EPID image breast contour. (b) Decent
alignment seen between the planning breast contour and the EPID image contour
3.2 Methods
As part of the retrospective study, positional correction and analysis was conducted for 30 pre-
viously treated 3DCRT breast patients. Due to anatomical differences between patients, and
the requirement to obtain adequate dose coverage across the treatment volume, each patient
had either two or three treatment fields per fraction. EPID images were acquired for a total of
255 fields across all 30 patients. EPIgray analysis was performed on all 255 EPID images.
For each field, the following data were acquired:
1. The initial %DDDRP.
2. The magnitude of shift required in the x and y dimensions within EPIgray to obtain the
alignment between the TPS breast contour and the breast contour seen on the EPID image
(correction method 2).
3. The resulting %DDDRP following positional correction.
4. The width of the separation between the lung and the DRP as shown in Figure 3.4.
For the majority of this project, the accuracy of treatment delivery was analysed using %DDDRP
as %DDvol was not available. However following the introduction of %DDvol similar analysis
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FIGURE 3.4: Separation measured between the lung and DRP
using the method above was performed for 23 of 30 patients. Seven patients were omitted from
this section of the study as they could not be re-imported into EPIgray for analysis. %DDvol
is an indicator of fractional treatment delivery accuracy. Therefore for these 23 patients, the
position corrected fractional %DDDRP was obtained to draw comparisons to %DDvol .
The approach of the retrospective study was designed to achieve the following aims:
1. Identify specific groups of patients at risk of having positional offsets on treatment (aim
1 of Chapter 2).
2. Decrease the current tolerance between the TPS predicted dose and the EPIgray calcu-
lated dose for specific groups of patients (aim 2 of Chapter 2).
3. Verify that the use of %DDDRP for treatment verification is appropriate and investigate
the usability of %DDvol for indication of treatment delivery accuracy at Christchurch Hos-
pital (aim 3 of Chapter 2).
3.3 Results
The results section of the retrospective study is presented in five parts:
• Subsection 3.3.1 presents the analysis of the magnitude and direction of shifts required
for patient positional correction for each group.
• Subsection 3.3.2 presents the numerical results of patient positional correction.
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• Subsection 3.3.3 presents the dosimetric effect of patient positional correction.
• Subsection 3.3.4 presents the effect of low density tissue in EPIgray reconstruction win-
dow on the %DDDRP.
• Subsection 3.3.5 presents the results of the investigation involving the use of %DDvol at
Christchurch Hospital.
3.3.1 Shifts Required for Patient Positional Correction
The following subsection presents the magnitude and direction of shifts required for contour
match correction to account for patient setup errors on treatment. The EPID position at which
the transmission images were acquired varies from patient to patient. In order to identify spe-
cific groups of patients at risk of having positional offsets on treatment, the EPID position was
corrected using the method described in subsection 3.1.1. In correcting for the EPID position,
the remaining discrepancy between the breast contour on the EPID image and the breast con-
tour from the TPS will indicate the differences in the patient positioning. EPID position correc-
tion was performed for all 255 fields to eliminate the variations in the expected EPID position.
Contour match correction described in subsection 3.1.2 was then performed to obtain the shifts
required for patient positional correction.
The patient is set up in 3-dimensions (3D) on treatment however the shifts for positional cor-
rections within EPIgray are based on a 2D image. The 3D patient positional shift directions on
treatment is shown in Figure 3.5. EPIgray positional corrections are performed in the x- and
y-dimensions. The shifts in the x-dimension corresponds to patient movement in the anterior-
posterior direction. However the patient could be offset to a position that is further away from
the radiation source (distal) or closer to the radiation source (proximal). The distal and proxi-
mal shifts of the patient will also require corrections in the x-dimension as a result of perform-
ing positional corrections for 3D shifts in 2D. Shifts in the y-dimension corresponds to shifts
in the superior-inferior direction of the patient. Both the magnitude and the direction of shifts
were considered in the x and y dimensions for all 255 fields. The results presented below are
grouped according to treatment laterality and breast size.
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FIGURE 3.5: Directions of Patient Shifts. Note: This figure also shows an axial view of the
treatment plan with the radiation beam direction and the irradiated treatment volume.
The position of the radiation beam determines the linac gantry position for treatment.
[44]
Breast Laterality
Shifts were implemented in the positive and negative directions for both lateralities. In order
to consider only the magnitude of these shifts, the absolute values of the shifts were used to
calculate the average magnitude of shift required for left and right breast fields. The average
shift required for left and right breast fields were 3.1±2.9 mm and 5.4±4.2 mm respectively.
The distribution of the absolute total magnitude of shift required for all fields of left and right
laterality are shown Figure 3.6.
Figure 3.6 reveals that left breast fields typically required a smaller magnitude of shift in com-
parison to right breast fields. In considering the most common shift magnitude for both lat-
eralities, it was found that 24% of left breast fields required an absolute shift between 0.0 mm
and 1.0 mm and 15.4% of right breast fields required an absolute shift of 3.0 mm to 4.0 mm.
Figure 3.6 also shows that right breast fields required a larger range of shifts in comparison to
left breast fields.
x-shift
The distribution of shifts required in the x-dimension is shown in Figure 3.7. The average mag-
nitude of shift required in the x-dimension for the left and right breast fields were 2.1±2.3 mm
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FIGURE 3.6: Distribution of absolute magnitude of shift required for positional correc-
tion of fields of both lateralities
and 3.9±3.3 mm respectively. Figure 3.7 and the average magnitude of shift required in the x-
dimension for patient positional correction indicate that right breast fields were not only more
likely to require a shift in the x-dimension in comparison to left breast fields, but right breast
fields were also more likely to require a larger shift than left breast fields. Figure 3.7 shows that
majority of the left breast fields required a shift in the negative direction which corresponds to
the patient offset to a position that is more posterior and/or distal from the expected position.
The majority of right breast fields required a shift in the positive direction which corresponded
to the patient being setup at a position that is more anterior and/or proximal than the expected
position. A two-sample t-test assuming unequal variances with a significance level of 5% was
conducted with the null hypothesis that there are no statistical differences between the shifts
required for left and right breast fields in the x-dimension1. The p-value obtained was 0.20. The
p-value obtained for the required x-shifts for each laterality indicates that the null hypothesis
cannot be rejected and there were no statistical differences in the x-shifts required between both
lateralities. Therefore the differences seen in the direction of shift required in the x-dimension
between lateralities was circumstantial.
1Note: T-tests have been performed throughout this study to investigate the statistical significance between data.
While it has been reported that t-tests are more robust for data of normal distributions, publications have revealed t-
tests are valid for sample sizes above 40 [45]–[48]. The suitability of t-tests were confirmed before use in all instances
throughout this study. All t-tests were performed using Microsoft Excel (2013), which employs t-test methodology
from a publication by Biometrika [49].
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FIGURE 3.7: Breast Laterality: x-shift required for positional correction
y-shift
The average magnitude of shift required in the y-dimension for left and right breast fields were
1.5±2.5 mm and 2.5±3.8 mm. These values indicate that on average right breast fields required
a larger magnitude of patient positional correction in y-dimension in comparison to left breast
fields. Figure 3.8 shows the distribution of the magnitude and direction of y-shifts required for
positional correction of fields within EPIgray. Figure 3.8 reveals that 60% of left breast fields
required a shift between 0.0 mm and -1.0 mm while 48% of right breast fields required a shift
between 0.0 and 1.0 mm. These results indicate that patient setup errors were more prominent
in right breast fields. The discrepancy seen in the direction of shift required was unexpected.
Results revealed that more left breast fields required a shift in the negative direction corre-
sponding to a patient shift in the superior direction for correction. In contrast, majority of the
right breast fields required a shift in the positive direction corresponding to a patient shift in
the inferior direction for correction. A statistical significance test was performed to investi-
gate the discrepancy seen in the direction of correctional shifts required for each laterality. A
two-sample t-test assuming unequal variances with a significance level of 5% was conducted
with the null hypothesis that there were no statistical differences between the shifts required
for left and right lateralities in the y-dimension. The p-values obtained was 0.01. The p-value
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obtained for the required y shifts indicate that the shifts required between left and right breast
fields were statistically different.
FIGURE 3.8: Breast Laterality: y-shift required for positional correction
By comparing Figures 3.7 and 3.8 it is evident that correctional shifts in the x-dimension was
more likely. Figures 3.7 and 3.8 indicate that there were larger patient positional set up errors
in the anterior-posterior and proximal-distal directions than in the superior-inferior direction.
Table 3.1 shows the number of fields of left and right lateralities requiring zero shifts or shifts
in a specific direction in x and y dimensions. In considering the x-dimension it was found that
the left breast fields do not exhibit a specific trend. That is, approximately a third of left breast
fields required a negative shift, a third of left breast fields required a positive shift and a third
of the left breast fields required zero shift for patient positional correction. In contrast, it was
found that right breast fields required negative shift followed by a positive shift, with very
few fields requiring no shift. While there were noticeable differences, the results of the t-test
indicated no significant differences between the shifts required in the x-dimension for left and
right breast fields. Considering the shifts in the y-dimension, it was found that majority of the
fields required zero shift for both lateralities. However, the left breast field required more neg-
ative shifts than positive shifts and the opposite was true for right breast fields. This finding
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suggests that left breast patients were more likely to be setup at a position that is inferior to the
expected position while right breast patients were more likely to be setup at a position that is
more superior to the expected treatment position.
TABLE 3.1: Number of left and right breast fields requiring negative, positive
and zero magnitude shifts in x and y dimensions for positional correction
x-dimension y-dimensionNumber
of Fields Left Breast Right Breast Left Breast Right Breast
Negative Shifts 42 (34.1%) 64 (48.5%) 34 (27.6%) 19 (14.4%)
Zero Shifts 40 (32.5%) 19 (14.4%) 72 (58.6%) 61 (46.2%)
Positive Shifts 41 (33.4%) 49 (37.1%) 17 (13.8%) 52 (39.4%)
Breast Size
The 30 breast patients were separated into two groups (small and large breasts) according to
maximum breast thickness visible on the acquired EPID images. Both groups had 15 patients.
The absolute magnitude of shifts required for patient positional correction were used to obtain
the average magnitude of shift required for small and large breast fields, which were 3.2±2.9
mm and 5.4±4.2 mm respectively. The distribution of the total magnitude of shift required for
small and large breast size fields is shown in Figure 3.9.
Figure 3.9 shows that small breast fields typically required smaller magnitude of shift with ap-
proximately 21% of small breast fields requiring a shift between 0.0 mm to 1.0 mm. Similarly
majority of large breast fields, although smaller in percentage in comparison to small breast
fields also required a shift between 0.0 mm and 1.0 mm. The range of shifts required is notice-
ably larger for large breast fields. This observation indicates that large breast fields were more
prone to setup errors on treatment.
x-shift
The distribution of shifts required in the x-dimension is shown in Figure 3.10. The average
magnitude of shift required in the x-dimension for small and large breast fields were 2.2 ± 2.0
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FIGURE 3.9: Distribution of total magnitude of shift required for positional correction of
fields grouped according to breast size
mm and 4.0 ± 3.4 mm respectively. The average magnitude of shift in the x-dimension indi-
cates large breast fields to require a larger shift than small breast fields. Figure 3.10 shows that
majority of the small breast fields required a shift between -1.0 mm and 0.0 mm whilst majority
of the large breast fields required a shift between 0.0 mm and 1.0 mm. Figure 3.10 also shows
that there was a larger range of shifts associated with the large breast fields in comparison to
small breast fields.
In order to investigate the differences in the direction of shift in the x-dimension, a t-test assum-
ing unequal variance with a significance level of 5% was conducted with the null hypothesis
that shifts required in the x-dimension between small and large breast fields were not statisti-
cally significant. The obtained p-value was <0.05. Therefore the null hypothesis can be rejected
and the shifts required in the x-dimension for small and large breast fields were statistically dif-
ferent.
y-shift
The average magnitude of shift required in the y-dimension for small and large breast fields
were 1.7±2.7 mm and 2.4±3.7 mm. This result indicated that large breast fields on average
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FIGURE 3.10: Distribution of x-shift required for positional correction of fields groups
according to breast size
required a larger magnitude of shift in the y-dimension than small breast fields. Additionally,
in drawing comparisons to the average magnitude of shift required for small and large breast
fields in the x-dimension, it was found that shifts in the y-dimension for both breast sizes were
of smaller magnitude. From Figure 3.11 it is evident that majority of small breast fields required
a shift between -1.0 mm and 0.0 mm whilst majority of the large breast fields required a shift
between 0.0 mm and 1.0 mm. These shifts indicate that small breasts were more likely to be
setup at a position that is inferior to the expected position and large breasts were more likely
to be setup at a position that is more superior to the expected treatment position. In comparing
Figures 3.10 and 3.11 it is found that in 3DCRT breast treatment there were more shifts in the x-
dimension for positional correction than in the y-dimension. This observation is in agreement
with the calculated average magnitude of shifts required for both breast sizes in the x and y-
dimensions. The results in this section therefore indicate that the setup errors were more likely
in the anterior-posterior and distal-proximal planes than in the superior-inferior plane for both
breast size groups.
In order to investigate the differences seen in the direction of shift in the y-dimension, a t-
test assuming unequal variance with a significance level of 5% was conducted with the null
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hypothesis that shifts required in the y-dimension for small and large breast fields were not
statistically different. The obtained p-value was <0.05. Therefore the null hypothesis can be
rejected and the shifts required in the y-dimension between small and large breast fields were
statistically different.
FIGURE 3.11: Distribution of y-shift required for positional correction of fields groups
according to breast size
Table 3.2 shows the number of fields grouped according to breast size requiring 2D shifts in
the positive and negative directions, as well as the number of fields that did not require any
shifts to correct for setup errors. In considering shifts in the x-dimension, the results in table 3.2
reveal that small breast fields were more likely to require a positive shift than a negative shift,
indicating small breast fields were more often setup at a position that was more anterior and/or
proximal than the expected position. In contrast, large breast fields were more likely to require
a negative shift than a positive shift, indicating large breast fields were more often setup at a
position that was more posterior and/or distal from the expected treatment position. Results in
table 3.2 also reveal that small breast fields were less likely to require a shift in the x-dimension
than large breast fields by approximately 10%. In considering y-dimensional shifts shown in
table 3.2, it was found that a large percentage of small breast fields required zero shift while
positive and negative shifts were approximately equivalent. Large breast fields were similar
to small breast fields in that a large number of fields did not require shifts in the y-dimension.
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However, table 3.2 shows that a large number of fields required a negative shift than a positive
shift, indicating that large breast fields were more often setup at a position that was more infe-
rior than the expected position. These results indicate that large breast fields were more prone
to setup errors as indicated by the smaller number of fields requiring no shifts in comparison
to small breast fields.
TABLE 3.2: Number of small and large breast fields requiring negative, positive
and zero magnitude shifts in x and y dimensions for positional correction
x-dimension y-dimensionNumber
of Fields Small Breast Large Breast Small Breast Large Breast
Negative Shifts 45 (34.9%) 61 (48.4%) 30 (23.3%) 56 (44.4%)
Zero Shifts 36 (27.9%) 23 (18.3%) 74 (57.3%) 59 (46.9%)
Positive Shifts 48 (37.2%) 42 (33.3%) 25 (19.4%) 11 (8.7%)
3.3.2 Numerical Results of Positional Correction Performed Within EPIgray
Following patient positional correction on EPIgray, the effects of contour match correction on
the resulting %DDDRP for differing treatment lateralities and breast sizes was investigated.
%DDDRP obtained from EPIgray before and after positional correction were used to categorise
the fields into one of four categories:
1. True pass2 (TP) - A field that was initially within ±5.0% tolerance before positional cor-
rection and remains within ±5.0% tolerance following positional correction.
2. True fail3 (TF) - A field that was initially outside of ±5.0% tolerance before positional
correction and remains outside of ±5.0% tolerance following positional correction.
3. False pass4 (FP) - A field that was initially within ±5.0% tolerance before positional cor-
rection and falls outside of ±5.0% tolerance following positional correction.
4. False fail5 (FF) - A fields that was initially outside of ±5.0% tolerance before positional
correction however falls within ±5.0% tolerance following positional correction.
2The terms ’true positive’ and ’true pass’ will be used interchangeably in this thesis.
3The terms ’true negative’ and ’true fail’ will be used interchangeably in this thesis.
4The terms ’false positive’ and ’false pass’ will be used interchangeably in this thesis.
5The terms ’false negative’ and ’false fail’ will be used interchangeably in this thesis.
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Breast Laterality
Of 255 fields analysed, 123 fields were left breast fields and 132 were right breast fields. Ta-
ble 3.3 shows the initial number of passing and failing fields before positional correction and
the number of passing and failing fields following positional correction. Results of table 3.3
show no major differences between the lateralities. However it was found that with positional
correction the left breast fields in this study produced more falsely failing results as indicated
by an increase in the number of corrected passes. In contrast, right breast fields produced
more falsely passing fields as indicated by a decrease in the number of corrected passes. Table
3.3 provides the number of initial passing and failing fields and corrected passing and failing
fields. However these numbers do not provide field specific information following positional
correction. That is, table 3.3 does not provide any indication of the number of fields that have
truly passed or failed or falsely passed or failed following positional correction on EPIgray. The
fate of the fields following positional correction is presented in table 3.4. Table 3.4 shows the
specific statistics that identify the fields that have truly passed and failed along with the fields
that have falsely passed and failed as a consequence of performing positional correction within
EPIgray.
TABLE 3.3: Initial number of passing and failing fields and corrected number of passing
and failing fields of left and right laterality
Numbers Left Right
Total number of fields 123 132
Initial Passes 108 (87.8%) 121 (91.7%)
Initial Fails 15 (12.2%) 11 (8.3%)
Corrected Passes 112 (91.1%) 115 (87.1%)
Corrected Fails 11 (8.9%) 17 (12.9%)
TABLE 3.4: The effect of positional correction on the fields of left and right laterality
Numbers Left Right
True Pass 101 (82.1%) 107 (81.1%)
True Fail 4 (3.3%) 3 (2.3%)
False Pass 7 (5.7%) 14 (10.6%)
False Fail 11 (8.9%) 8 (6.1%)
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The statistics shown in table 3.4 do not show any significant differences between left and right
breast fields in the number of true passes, true fails and false fails. However, the number of
false passes between the two lateralities reveal that right breast fields were almost twice as
likely to produce a falsely passing result than left breast fields. Following investigation of
these failing results it was found that six of the falsely passing right breast fields have come
from one patient. This particular patient had three fields per fraction. Inaccurate acquisition
of EPID images over two fractions had led to six falsely passing results. Inaccurate acquisition
of EPID images refer to not acquiring the entire field within the image. Therefore ignoring the
EPIgray results for this patient, there were no significant differences between the lateralities
when considering the number of truly passing and failing fields and the number of falsely
passing and failing fields. However, these results emphasise the need for verification of proper
alignment between the EPID image and the TPS contours to ensure that the given %DDDRP is
reflective of the treatment delivered to the patient.
Breast Size
Table 3.5 shows the initial and the positional corrected number of passing and failing fields.
Initial observation of table 3.5 reveals that the effect of positional correction on EPIgray is not
breast size dependent. Both small and large breast fields show similar number of passes and
fails both before and after positional correction within EPIgray. However for in depth analysis,
it is important to categorise these fields as true passes and true fails as well as false passes and
false fails to truly examine the effect of positional correction on the %DDDRP for each breast
size. Table 3.6 shows specific statistics that identify the fields that have truly passed and failed
as well as fields that have falsely passed and failed following positional correction on EPIgray.
TABLE 3.5: Initial number of passing and failing fields and corrected number of passing
and failing fields of small and large breast size groups
Numbers Small Large
Total number of fields 129 126
Initial Passes 117 (90.7%) 112 (88.9%)
Initial Fails 12 (9.3%) 14 (11.1%)
Corrected Passes 116 (89.9%) 112 (88.9%)
Corrected Fails 13 (10.1%) 14 (11.1%)
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TABLE 3.6: The effect of positional correction on the fields of small and large breast sizes
Numbers Small Large
True Pass 109 (84.5%) 99 (78.6%)
True Fail 5 (3.9%) 1 (0.8%)
False Pass 8 (6.2%) 13 (10.3%)
False Fail 7 (5.4%) 13 (10.3%)
Results shown in table 3.6 indicate that small breast fields were more likely to truly pass than
large breast fields. However the total number of passing fields for small and large breast fields
was found to be 90.7% and 88.9%. Therefore, these results indicate that the breast size does
not affect the %DDDRP following positional correction within EPIgray as there were similar
number of passing and failing fields. However results shown in table 3.6 reveal that large
breast fields were more likely to produce falsely passing and falsely failing results than small
breast fields. Considering the results shown in tables 3.5 and 3.6 and considering only the
fields that have failed, it was found that only 7.1% of the large fields that produced a failing
result were true fails, while 92.9% were falsely failing fields. In contrast, the small breast fields
that produced a failing result showed more of an even divide between truly failing fields and
falsely failing fields. 41.7% of the initially failing small breast fields remained as failing fields
following positional correction and 58.3% of initially failing small breast fields were within
tolerance following positional correction. This observation at this point could be circumstantial.
A t-test was performed to identify significant differences between small and large breast fields.
The result of the t-test will be discussed in subsection 3.3.3.
3.3.3 Dosimetric Effect of Positional Correction Within EPIgray
The %DDDRP is expected to change following positional correction within EPIgray because the
environment over which the reconstruction is performed has changed. This section presents the
dosimetric results of performing positional corrections. The dosimetric effects of the positional
correction were subsequently analysed according to treatment laterality and breast size.
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Breast Laterality
The %DDDRP is calculated using equation 1.1 from Chapter 1. It is important to note that neg-
ative and positive %DDDRP indicate that EPIgray has calculated a dose to the DRP that is less
than and more than the TPS planned dose respectively. Therefore in order to find the average
%DDDRP of each laterality, the absolute %DDDRP were used. This section only addresses the
magnitude of the %DDDRP not whether the %DDDRP indicated an underdose or an overdose.
The average %DDDRP before positional correction for left and right breast fields was found
to be 3.4±3.9% and 3.2±3.7% respectively. Acknowledging the inherent uncertainties associ-
ated with the EPIgray dose calculation algorithm, these numbers are comparable to each other.
Following positional corrections within EPIgray, it was found that the average %DDDRP is
2.4±1.8% for left breast fields and 2.7±3.0% for right breast fields. Results have indicated an
improvement in the %DDDRP for both left and right breast fields. In order to find evidence of
statistical difference between left and right lateralities, a two-sample T test assuming unequal
variances with a significance level of 5% was conducted with the null hypothesis that there
were no statistical differences in the %DDDRP of left and right lateralities following positional
correction. The p-value obtained was 0.43. This p-value indicates that the null hypothesis can-
not be rejected. Therefore the small difference in the average %DDDRP values after positional
correction between left and right lateralities was a result of the uncertainties associated with
EPIgray itself.
Distribution of The Percentage Dose Difference
For EPIgray to be an exact indicator of the treatment delivered to the patient, the %DDDRP
should be 0.0%, given that there were no uncertainties associated with treatment delivery.
However, underdoses and overdoses according to EPIgray are likely as a result of a range of
uncertainties described in Chapter 5. Due to the complexity of radiotherapy treatments there
are numerous possibilities of delivering suboptimal radiotherapy. In reality the distribution of
dose delivery would take a similar appearance to the distribution shown in Figure 3.12.
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Previously only the absolute magnitude of the %DDDRP was considered. Figures 3.13 and
3.14 show the distribution of the %DDDRP of left and right breast fields, before and after posi-
tional correction. These figures address the magnitude of the %DDDRP calculated by EPIgray
as well as whether the %DDDRP indicated an underdose or an overdose at the DRP according
to EPIgray.
FIGURE 3.12: Realistic distribution of dose delivery in radiotherapy
FIGURE 3.13: Distribution of percentage dose difference of left breast before and after
positional correction
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FIGURE 3.14: Distribution of percentage dose difference of right breast before and after
positional correction
Initial observation of Figures 3.13 and 3.14 revealed that following positional correction the
%DDDRP of both lateralities lie closer to 0%. Fields that have a %DDDRP greater than 10% were
considered outliers. It was found that most outliers following positional correction presented
a %DDDRP of less than ±5.0% tolerance.
Following the positional correction, it was found that 8.9% of the left breast fields and 11.4%
of the right breast fields indicated out of tolerance results that required further investigation
to prove they are clinically acceptable. All left breast fields that exceeded clinical tolerance
indicated an overdose at the DRP. Right breast fields in contrast, indicated both underdoses
(5.3% of right breast fields) and overdoses (6.1% of right breast fields) lying outside the clinical
tolerance. Regardless of whether EPIgray indicated underdoses or overdoses at the DRP, both
lateralities exhibited similar rates of passing and failing fields overall. Following investigation,
it was determined that the failing fields failed as a result of inaccurate acquisition of the EPID
image itself (where the entire EPID image had not been properly captured on treatment), rather
than a dosimetric inaccuracy in the treatment delivery.
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Figures 3.15 and 3.16 show the relationship between the TPS dose and the position corrected
EPIgray dose of all left and right breast fields respectively. These figures also show the line
of best fit for each laterality along with the equation for the line of best fit and the R2 value.
The gradient of the line of best fit of both lateralities indicated a near one-to-one relationship
between the TPS and EPIgray doses. The y-intercepts of the line of best fits was found to be -2.6
for left breast fields and -5.1 for right breast fields. These numbers indicate the offset between
the TPS dose and the EPIgray doses for the population under investigation. This finding sug-
gests and supports the earlier observations that there were larger offsets between the TPS and
EPIgray doses for right breast fields than left breast fields. The R2 values provide statistical in-
dication of how close the data were fitted to the regression line. The larger, the R2 the better the
model fits the data [50]–[52]. The R2 values of the line of best fit of both lateralities indicated a
direct linear relationship between the TPS doses and the EPIgray doses. Figure 3.16 shows the
presence of an outlier. This outlier will cause R2 to be lower than the currently displayed value
for right breast fields. Investigation of this outlier revealed an issue associated with the EPID
image itself and therefore will be ignored. Ignoring this single outlier, the gradient of the line
of best fit remained as 1.0 however, the R2 value increased, indicating a stronger direct linear
relationship between the TPS dose and the EPIgray dose.
FIGURE 3.15: TPS dose and EPIgray doses of all left breast fields (dotted line represents
the line of best fit)
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FIGURE 3.16: TPS dose and EPIgray doses of all right breast fields (dotted line represents
the line of best fit). The circled point is an outlier.
Breast Size
The initial average %DDDRP between the TPS dose and the EPIgray dose for small and large
breast fields was found to be 2.9±2.1% and 3.6±4.9% respectively. Following positional correc-
tion the average %DDDRP was found to be 2.6±1.9% for small breast fields and 2.4±2.8% for
large breast fields. While the average %DDDRP was initially larger for large breast fields, this
value may be a consequence of %DDDRP outliers skewing the data set. Following positional
correction however, both small and large breast fields had comparable average %DDDRP.
A two-sample T test assuming unequal variances with a significance level of 5% was conducted
for small and large breast fields in order to obtain evidence of statistical difference. The null hy-
pothesis assumed that there were no statistical differences between position corrected %DDDRP
of small and large breast fields. The p-value obtained was 0.63. This p-value indicates that the
null hypothesis cannot be rejected and therefore the differences seen in the average dose dif-
ferences between small and large breast fields may have occurred by chance and these samples
were not statistically different.
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Figures 3.17 and 3.18 show the distribution of the %DDDRP of small and large breast fields be-
fore and after positional correction respectively. These figures indicate that small breast fields
have smaller range of %DDDRP than large breast fields. Following positional correction the
%DDDRP range was comparable for both breast sizes. This finding provided an explanation for
the higher average %DDDRP observed for the large breast fields before positional correction.
Following positional correction, the %DDDRP of small breast fields range from -7.0% to 10.0%
and the %DDDRP for large breast field range from -7.0% to 9.0%. It is evident through Figures
3.17 and 3.18 that positional correction within EPIgray is effective for both breast sizes.
Investigation of outliers post positional correction, revealed that these fields have come from
two patients. Investigation has revealed improper acquisition of EPID image for dose calcula-
tion. Significant dosimetric errors have not occurred.
FIGURE 3.17: Distribution of percentage dose difference of small breast fields before and
after positional correction
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FIGURE 3.18: Distribution of percentage dose difference of large breast fields before and
after positional correction
Figures 3.19 and 3.20 show the relationship between the TPS doses and position corrected
EPIgray doses of all small and large breast fields respectively. These figures also display the
line of best fit for each breast size and the corresponding equation for the line of best fit. The
gradient of the line of best fit was found to be 1.00 for small breast fields and 1.05 for large
breast fields. These values are sufficiently close to one indicating that there is a direct linear
relationship between the TPS and EPIgray doses. The y-intercepts of the line of best fits was
found to be 1.5 for small breast fields and -6.9 for large breast fields. These numbers indicate
the offset between the TPS and the EPIgray doses for small and large breast fields. It was
found that there was a larger difference between the TPS dose and the EPIgray dose for large
breast fields than small breast fields. The R2 values of the line of best fit for small and large
breast fields was found to be 0.9. The magnitude of these R2 values support the strong linear
relationship indicated by the gradient between the TPS and the EPIgray doses for both breast
sizes.
3.3. Results 49
FIGURE 3.19: TPS dose and EPIgray doses of all small breast fields (dotted line repre-
sents the line of best fit)
FIGURE 3.20: TPS dose and EPIgray doses of all large breast fields (dotted line represents
the line of best fit)
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3.3.4 Effect of Low Density Tissue on EPIgray Reconstructed Dose
Publications in the literature have revealed that the dosimetric accuracy of EPIgray determined
doses decrease in areas of highly variable tissue densities [40]. The presence of lung tissue near
the treatment volume of breast treatments does to a certain extent affect the reconstructed dose
at the DRP. Additionally, the position of the DRP is also variable from patient to patient. This
section presents the results obtained in the investigation of the EPIgray reconstructed dose
dependency on the position of the DRP. The relationship between the lung and DRP separa-
tion and the position corrected %DDDRP was analysed and the results are shown in Figure 3.21.
FIGURE 3.21: Relationship between the DRP and lung separation and position correction
%DD. The points in the oval are %DD measured on the lung-breast tissue interface and
therefore will be ignored
Figure 3.21 shows no significant relationship between %DDDRP following positional correction
and the separation between the DRP and the lung. It was expected that the closer the DRP
is to the lung, the larger the absolute magnitude of %DDDRP, however Figure 3.21 does not
reveal a specific trend. Other relevant measurements made to investigate the effect of lung on
the EPIgray reconstructed doses were the width of the lung seen on the EPID image and the
distance between the DRP and the anterior breast surface.
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The width of the lung on the EPID images did not show much variation as treatments are ac-
tively planned to avoid lung in field. The width of the lung in field did not show any trends
with the EPIgray reconstructed dose and therefore results are not shown here. The distance be-
tween the DRP and the anterior breast surface strongly correlates with breast size and therefore
results will not be presented to avoid repetition.
3.3.5 Alternative Method for EPIgray Dosimetric Analysis
The distribution of the resulting fractional %DDvol and %DDDRP following positional correc-
tion for 23 of 30 patients are shown in Figure 3.22. From this figure, it is evident that the volume
analysis had indicated the treatment volume to have consistently received a lower dose than
the intended fractional dose, while the DRP method had indicated fractional doses that were
mostly larger than the intended doses. From this figure, it is evident that there is a bias in the
selection of the DRP. Additionally, the disagreement between %DDvol and %DDDRP indicated
that the DRP may not be representative of the treatment volume. The DRP is chosen to be at a
point where the dose is reproducible and is also in an area where the dose is not highly vari-
able. The DRP will also be located in a region with minimal variation in tissue densities. In
contrast, the 50 points generated by EPIgray is based on the maximum isodose that covers 50%
of the treatment volume. These points are randomly generated and therefore there is minimal
bias associated with the selection of these points. Consequently some points may be located
near low density regions which will add to the statistical uncertainty of the %DDvol .
Currently, the tolerance for %DDvol has been automatically set to ±5.0%. In order to investi-
gate the effectiveness of this tolerance to indicate falsely passing fields and potential inaccurate
treatments, the fractional %DDvol magnitude was checked against the %DDDRP of each field for
the patients of the retrospective study. A total of 66 fractions were analysed. Results have re-
vealed that 20 of 23 patients remained within ±5.0%. Two of the three failing %DDvol patients
had falsely passing fields following analysis using %DDDRP method. The remaining patient
produced a failing %DDvol result however did not have failing results both before and follow-
ing positional correction. While there was a failing %DDvol patient with no failing result, it
not advisable to increase the %DDvol tolerance as this may permit the passing of other failing
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FIGURE 3.22: Percentage dose difference distribution acquired for fields using the dose
to the DRP and the average dose of the EPIgray volume
results. It must be accepted that the set tolerance will never entirely encompass the entire pop-
ulation seen in the clinic. Consequently identifying a falsely passing field over falsely failing
field is of more importance as the former would have the most significant dosimetric impact if
it was missed clinically.
Additionally during the investigation of the %DDvol , the standard deviation associated with
the reconstructed doses were also noted for each fraction. It was found that fractions of pa-
tients that exceeded a standard deviation of 0.1 Gy had at least one falsely passing field within
the fraction following positional correction using %DDDRP analysis. This finding allows the
standard deviation of the reconstructed dose to also indicate that an unexpected treatment
may have occurred.
3.4 Discussion
This section will combine the results from subsections 3.3.1 to 3.3.3 and present the discussion
for breast laterality and breast size separately. This will be followed by a discussion of the
effect of having low density tissue in the EPIgray reconstruction environment on the %DDDRP.
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Lastly, the clinical use of %DDvol will be discussed through comparisons to current practice at
Christchurch Hospital.
3.4.1 Breast Laterality
The average magnitude of the total shift required for positional correction indicated that right
breast fields on average required larger positional corrections than left breast fields. Shifts anal-
ysis performed separately in x and y-dimensions found right breast fields to not only require
corrections more frequently in both dimensions but these corrections were also found to be of
larger magnitude in comparison to left breast fields. These results have suggested that right
breast patients were more at risk of having positional offsets on treatment. X-dimensional shift
analysis revealed differences between left and right breast fields. A t-test conducted to investi-
gate whether the shifts required between right and left breast fields were statistically different
from each other revealed that the data sets were not significantly different. Therefore the dif-
ferences observed were concluded be circumstantial.
Y-dimensional shift analysis revealed right breast fields to require positional corrections more
frequently than left breast fields. Right breast fields on average also required positional cor-
rection of larger magnitude in comparison to left breast fields. The direction of shifts required
were in the opposite direction for each laterality. The results of the t-test to test for statistical
significance revealed that the shifts required in the y-dimension for left and right breast fields
were statistically different. Following consultation with the treatment staff there were no obvi-
ous differences in the setup of the patients of different lateralities on treatment. Therefore the
observed differences in the shifts required in the y-dimension was unexpected. Consequently,
the cause of this result currently remains inconclusive and requires further investigation. A
possible cause for this difference may be how the patient is setup at simulation and conse-
quently at every fraction. Patients are asked to clasp one of their hands to the other arm’s wrist
above the their head to prevent their arms from receiving unnecessary radiation. At treatment,
the patient will be asked to place their arms above their head at a position they find the most
comfortable. Consequently, the clasping hand may vary between fractions. This may give rise
to a small patient shift in position with a slight rotation depending on which arm is holding
the other. This positional variation may give rise to the differences seen between right and left
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breast fields. Another proposed cause may be a result of which side of the patient the radiation
therapist is standing on when setting up the patient in the treatment position. Parallax error
at the position the radiation therapist is at when setting up the patient may also contribute
to the differences seen between the shifts required for both lateralities. As there were no ap-
parent biases in the planning, setup or treatment of left and right breast patients, the current
differences seen between the lateralities remains inconclusive until further investigation on fu-
ture patients. However, analysis of shift directions as part of this study have suggested that
left breast patients were more likely to be setup in a position that is inferior to the expected
treatment position and right breast patients were more likely to be setup in a position that
is superior to the expected treatment position. The setup offsets of patients in the anterior-
posterior direction and the proximal-distal planes were more prominent than setup offsets in
the superior-inferior directions for both lateralities. The shift analysis has revealed that right
breast patients were more at risk of having setup errors on treatment.
Numerical analysis of fields following positional correction has revealed that there were no
significant differences between truly passing and failing fields and falsely passing and failing
fields of both lateralities, ignoring improper EPID image acquisitions. Nevertheless, it was
found that false results were likely for both lateralities. Therefore these results emphasise the
need for the verification of proper alignment of the EPID image to the TPS contours to ensure
that the given %DDDRP is reflective of the treatment delivered to the patient.
Dosimetric analysis of the effect positional correction has on the %DDDRP between lateralities
reveals that the average %DDDRP of left and right breast fields were comparable before and
after positional correction. In both laterality groups, it was found that the average %DDDRP
improved with positional correction within EPIgray. A test for statistical difference has re-
vealed that there were no significant differences between the positional corrected %DDDRP of
both lateralities. This finding is in agreement with the results found in the numerical statistics
section in which there were comparable number of passing and failing fields before and after
positional correction.
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Figures 3.13 and 3.14 have provided evidence that positional correction within EPIgray results
in a smaller magnitude of %DDDRP. This indicates a better agreement between the TPS planned
dose and the dose delivered to the patient according to EPIgray. Investigation of failing fields
following positional correction of both lateralities indicated incorrect acquisition of EPID im-
ages for EPIgray analysis. It was found that both left and right breast fields had similar rates
of passing and failing fields. 3DCRT treatments of the breast are planned to avoid dose to the
heart and the ipsilateral lung. Therefore the treatment process should result in very minor dif-
ferences seen in the %DDDRP between the left and right lateralities. The dosimetric analysis
of the effect positional correction has on the %DDDRP has identified no significant differences
between the left and right lateralities. This finding is consistent with the results of the shifts
required for positional correction and the results of the numerical analysis in that there are no
major discrepancies between the breast lateralities.
The %DDDRP provided by EPIgray is an indication of the treatment delivery accuracy accord-
ing to EPIgray. The dosimetric analysis of left and right breast fields also established the level
of agreement between the TPS planned dose and the EPIgray reconstructed dose to the DRP.
The relationship between the TPS dose and the EPIgray dose was a direct, linear one-to-one re-
lationship. The R2 values obtained for the relationship between the TPS and the EPIgray doses
of both lateralities showed strong statistical agreement. Therefore the dosimetric analysis of
the %DDDRP has revealed that EPIgray does not indicate significant differences between left
and right breast fields.
3.4.2 Breast Size
The average magnitude of the total shift required and the distribution of the magnitude of po-
sitional correction indicated that large breast fields required a larger positional correction than
small breast fields. Analysis of the magnitude of shift required in the x- and y-dimensions re-
vealed large breast fields to not only require corrections more frequently but also to require a
larger magnitude of shift than small breast fields. These results have suggested that large breast
patients were more at risk of having setup errors on treatment in both x- and y-dimensions. Re-
sults have shown that there was a difference in the direction of shift required in the x-dimension
and y-dimensions between small and large breast fields. In the x-dimension it was found that
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small breast patients were more likely to be setup at a position that is more posterior and/or
distal from the expected treatment position and large breast patients were more likely to be
setup at a position that is more anterior and/or proximal from the expected treatment position.
Similarly in considering the shifts in the y-dimension it was found that small breast patients
were more likely to be set up at a position that is inferior to the expected position and large
breast patients were more likely to be setup at a position that is more superior to the expected
treatment position. A t-test indicated that shifts required for positional correction of small and
large breast fields were statistically different.
Following consultation with the treatment staff it was the general consensus that larger breast
patients were more difficult to setup on treatment. While the planning processes and the pa-
tient processes through the radiotherapy clinic are the same for breast patients of all breast
sizes, it was found that CT simulation stages and the treatment setup are more difficult for
large breast patients. At the CT simulation stages, the patient would receive tattoos at points
where the CT room lasers are incident upon their skin with the patient in their treatment po-
sition. These are the reference markers the staff on treatment will use to setup the patient in
the same position for treatment delivery. With larger breast patients, CT simulation staff have
indicated that placement of tattoo is often made difficult with having more tissue in the tattoo
region. Additionally with ageing patients, there is a loss of tissue elasticity and therefore the
position of the tattoo is more prone to sag. Consequently when the patient is being setup on
treatment, the treatment staff have difficulty aligning all reference tattoos to the lasers of the
treatment room. The treatment staff have more frequently identified notable uncertainties as-
sociated with patient setup of larger breast size. However, these positional uncertainties are
within clinical tolerance and therefore treatment proceeds without considerable risk to the pa-
tient.
The results of numerical analysis of small and large breasts fields before and after positional
correction do not indicate significant differences between the breast sizes. Both breast sizes
indicate similar rates of passing and failing fields. However it was found that large breasts
were more likely to produce false results. Nevertheless, both small and large breast groups
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have shown false results. Falsely failing fields are not of major concern as treatment profes-
sionals will be alerted to these fields as initially failing fields and therefore an investigation is
initiated to confirm that accuracy of the treatment. However, the falsely passing fields are of
major concern as these fields present as clinically passing fields and may go unnoticed. Cur-
rently there are no measures in place to ensure that the dose has been reconstructed over the
correct environment for accurate representation of dose delivered to the patient. The impli-
cation of this result is that while majority of the initial passes within EPIgray remain a pass
following positional correction, a method of identifying falsely passing fields is required. This
may be achieved by either implementing a more sensitive %DDDRP tolerance or by performing
positional correction within EPIgray for all fields regardless of breast size. Both these options
would require a change in the current clinical practice.
Dosimetric analysis of the effect positional correction has on the %DDDRP between breast sizes
reveals that the average %DDDRP before positional correction is smaller in magnitude for small
breast fields than large breast fields. With positional correction the average %DDDRP improved
for both small and large breast fields and were comparable. It was found that while the aver-
age %DDDRP for small breast fields decreased in magnitude indicating a better agreement of the
EPIgray dose with the TPS dose, the decrease in the %DDDRP following positional correction is
negligible. In contrast a considerable decrease in the average %DDDRP was seen for large breast
fields. This finding is in agreement with the findings of the shifts required for positional correc-
tion. Large breast fields required shifts more frequently and the magnitude of these shifts were
also larger in comparison to small breast fields. Therefore, with larger magnitude of positional
correction, the environment over which the dose reconstruction is performed within EPIgray
is more drastically changed. This results in a larger difference between the initial %DDDRP and
position corrected %DDDRP. Following positional correction, the average %DDDRP between
small and large breast fields were comparable. The result of a t-test conducted with the null
hypothesis that there were no statistical differences between the positional corrected %DDDRP
of small and large breast fields indicated that there were no significant differences between the
breast sizes. Therefore this result indicates that EPIgray does not exhibit any bias associated
with breast size.
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Figures 3.17 and 3.18 have provided evidence that positional correction within EPIgray results
in a smaller magnitude of %DDDRP for most fields. Consequently this indicates a better agree-
ment between the TPS planned dose and the dose delivered to the patient according to EPIgray.
Investigation of failing fields following positional correction of both lateralities indicated in-
correct acquisition of EPID images for EPIgray analysis therefore no further investigation was
necessary.
The dosimetric analysis of small and large breast fields also established the agreement between
the TPS planned dose and the EPIgray reconstructed dose to the DRP. The relationship between
the TPS dose and the EPIgray dose was a direct, linear one-to-one relationship. The R2 val-
ues obtained for the relationship between the TPS and the EPIgray doses for both breast sizes
showed strong statistical agreement. Therefore the dosimetric analysis of the %DDDRP has re-
vealed that EPIgray does not indicate significant differences in dose calculations between small
and large breast fields.
3.4.3 Low Density Tissue Effect on Reconstructed Dose
Literature has revealed that the potential presence of the ipsilateral lung, a low density tissue
within the reconstruction environment may contribute to the uncertainty associated with the
EPIgray reconstructed dose. To investigate this effect in 3DCRT breast treatments, the sep-
aration between the lung and the DRP was investigated as a function of position corrected
%DDDRP. The results section has revealed that the presence of the lung in the reconstruction
window does not have a significant relationship with %DDDRP. Previous publications have
revealed that with low density tissues in field, the reconstructed dose given will be smaller
than expected as a result of decrease in scatter in the reconstruction environment [39]. With
this hypothesis, the expected result of this section of the study was that with increasing separa-
tion between the DRP and the lung, the lower the %DDDRP will be. However 3.21 shows that
there was no significant relationship between the DRP and lung separation and the %DDDRP
for breast fields of both lateralities and sizes. This finding provides clinical evidence that the
current placement of the DRP with reference to the lung position was not significantly affected
by the limitations of EPIgray reconstruction algorithm in 3DCRT breast treatments.
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3.4.4 Alternative Methods of Dosimetric Verification
Analysis using the fractional %DDDRP and the %DDvol has revealed that there is a bias asso-
ciated with the selection of the DRP. The DRP is typically chosen to provide the most reliable
dose. While it is clinically useful to reliably quantify the accuracy with which the treatment
has been delivered to the patient, the %DDDRP is an indicator of the dose delivered to a single
point dose. The use of %DDvol could be clinically beneficial because it provides an indication
of treatment accuracy to a volume rather than a single point. The %DD obtained using both
methods has revealed that the DRP dosimetric analysis typically provides a dose that is greater
than the expected dose whilst the %DDvol obtained using the volume method provides a dose
that is lower than expected dose. Both %DDDRP and %DDvol can be simultaneously true, in
that the dose to the DRP was greater than expected dose while the dose to a treatment volume
was lower than expected and therefore it is difficult to claim one method to be more reliable
than the other.
Unlike the dosimetric analysis using the DRP method which provides a %DDDRP for every
field within a fraction, the %DDvol only provides the fractional %DD due to EPIgray software
limitations. Therefore, in clinical situations when a failing fraction has occurred, the %DDvol
will not provide additional information regarding which fields are responsible for the failed
result. Results show that the use of %DDvol may be clinically beneficial however its limitations
of providing only fractional information means that other dosimetric methods must also be
in place to provide other immediate information if necessary. A %DDvol tolerance of ±5.0%
and a ±0.1 cGy tolerance for reconstructed dose standard deviation has been recommended
following analysis of the retrospective study patients using %DDvol . These tolerances have
shown to effectively identify falsely passing fields.
3.5 Conclusions
From the retrospective study, it was found that when considering treatment laterality and
breast size, right and large breasts were more at risk of having setup errors respectively. The
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direction of the shift required for positional correction varied based on the breast size and later-
ality. For all breast patients, it was found that patient positional offsets in the anterior-posterior
and proximal-distal directions were more common than patient offsets in the superior-inferior
direction.
Numerical and dosimetric analysis of the %DDDRP of fields of different lateralities and breast
size have indicated that false results are a possibility across both treatment lateralities and
breast groups. Currently there are no measures in place to ensure that %DDDRP automatically
calculated by EPIgray has been calculated over the appropriate treatment environment using
the correct treatment parameters. Therefore it becomes important to verify patient and EPID
position with EPIgray before using %DDDRP as an indicator for treatment accuracy. It is rec-
ommended that either a new tolerance for the %DDDRP that is more sensitive to false results is
implemented or positional verification is performed for every field for at least the first fraction
to ensure no major errors have occurred and to reliably use EPIgray as an IVD system.
The retrospective study has revealed that the %DDDRP provided by EPIgray is unaffected by
the treatment laterality and breast size following positional correction within EPIgray. There
were similar numbers of passing fields following positional correction on EPIgray between
lateralities and breast sizes. This result provides clinical evidence that the EPIgray dose calcu-
lation algorithm does not exhibit significant biases for a particular treatment laterality or breast
size. The relationship between the TPS and the EPIgray doses also indicated a direct linear
relationship. Therefore, evidence from the retrospective study provides clinical validation for
using EPIgray as an IVD system. However, the agreement between EPIgray and TPS doses is
not sufficient. An independent dosimetric system must verify the doses delivered to the patient
to ensure that the EPIgray reconstructed doses are sufficiently accurate and are representative
of the dose delivered to the patient, as found in Chapter 4.
The effect of having low density tissue in the field on the EPIgray reconstructed dose was
investigated using the lung and DRP separation. This investigation was launched following
literature review which indicated that the accuracy of EPIgray reconstructed doses is dimin-
ished with decreasing distance between the point of dose reconstruction and rapidly varying
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tissue densities. Following analysis of a range of separations between DRP and lung, it was
found that the presence of the ipsilateral lung tissue in the field of reconstruction does not sig-
nificantly affect the %DDDRP.
Investigation of using %DDvol at Christchurch Hospital revealed that there is a bias associ-
ated with the selection of the DRP. Results of this investigation have indicated that it would be
clinically beneficial to implement %DDvol which provides an indication of treatment accuracy
using volume rather than a single point. However, the limitation of this method is such that
%DDvol will need to be used in conjunction with %DDDRP. Additionally the investigation of us-
ing %DDvol as a treatment accuracy indicator involved %DDvol analysis of patients who have
previously been treated at Christchurch Hospital. Whilst these patients had small positional
errors associated with their treatment, these errors were not dosimetric errors. The %DDvol
obtained were for positional corrected fields and were compared to fractional %DDDRP of po-
sitional corrected fields. A tolerance of ±5.0% is recommended for implementation of %DDvol
for routine clinical use. Additionally the use of the standard deviation associated with the mean
reconstructed dose using the volume method is also recommended for identification of falsely
passing fields. It is recommended that for a fractional standard deviation of greater than 0.1
Gy, positional correction should be performed with EPIgray and the %DDDRP of each field is
verified to have truly passed. Investigation of the relationship between %DDDRP and %DDvol
with positional offsets will need to be tested before using the DOSIsoft recommended volume
based dosimetric analysis for verification of the dose delivered to the patient.
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The retrospective study showed that patient setup errors on treatment result in EPIgray pro-
viding an inaccurate %DDDRP as a result of the dose reconstruction performed over an incor-
rect environment. Positional correction within EPIgray minimises the uncertainties associated
with EPID and patient positioning on treatment. Consequently, positional correction within
EPIgray provides a %DDDRP that is more representative of the dose delivered to the patient.
Additionally, the retrospective study has provided confirmation that there is acceptable agree-
ment between the TPS dose and the delivered dose regardless of treatment laterality or breast
size. However validation that the %DDDRP is sufficiently close to the delivered dose using
an independent dosimetry system is required to reliably use EPIgray as an IVD system. The
retrospective study has also identified differences between routinely used %DDDRP and the
DOSIsoft recommended %DDvol for dosimetric analysis. Therefore, an investigation of the use
of %DDvol with setup errors will need to be conducted to verify the recommended clinical tol-
erance.
A phantom study was undertaken to achieve the following aims:
1. To quantify the effects of setup errors on the %DDDRP in order to decrease the current
%DDDRP tolerance of ±5.0% between the TPS dose and the EPIgray reconstructed dose
for 3DCRT breast treatments if indicated.
2. To verify the fractional %DDvol tolerance to minimise the number of false results.
3. To verify the ability of EPIgray to detect discrepancies in patient positioning on treat-
ment through identification of discrepancies between the TPS dose and the EPIgray re-
constructed dose.
The phantom study was performed using a phantom specifically designed to achieve the aims
listed above.
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4.1 Breast-Lung Phantom
4.1.1 Purpose
In order to validate the use of EPIgray as an IVD system, the breast-lung phantom was de-
signed to allow dosimetric measurements to be acquired using two established dosimeters: an
IC and radiochromic film. The breast-lung phantom would therefore allow comparisons to be
made between the TPS predicted dose, EPIgray calculated dose and the delivered dose mea-
sured on treatment. The results from this investigation would validate the use of EPIgray as an
IVD system.
The phantom would also be used to isolate patient setup errors on treatment in terms of di-
rection and their effects on %DDDRP. The phantom would be shifted by a known distance on
treatment and the doses at these corresponding offsets would be measured. The comparison of
the EPIgray doses to the IC and film doses at the offset positions would provide information
regarding EPIgray reliability with patient setup errors on treatment.
Lastly, the phantom would be used to investigate the relationship between %DDDRP and %DDvol
with setup errors to validate the recommended fractional %DDvol tolerance for treatment veri-
fication of 3DCRT breast treatments.
4.1.2 Phantom Design Aims
1. In order to use the proposed phantom in place of a patient receiving radiation treatment
to the breast, the phantom must be representative of a patient. The phantom would have
two components. The first component would represent the target volume, the entire
breast and the second component would represent the main OAR, the ipsilateral lung.
2. The phantom should allow dosimetric measurements to be made during treatment de-
livery and therefore it must allow placement of an IC and radiochromic film in relevant
locations without significantly affecting the dose to be measured.
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3. The phantom would be used to investigate the effects of setup errors on the %DDDRP
and therefore the phantom must be easy to move and position on treatment in order to
simulate changes in the patient position.
4.1.3 Phantom Design
Tissue-Substitute Materials
In order for the phantom to be used in the place of a patient receiving radiation treatment to
the breast, the phantom must achieve tissue equivalency in terms of its radiation absorption
and scatter properties. In considering tissue equivalency the physical density, electron density,
attenuation coefficient and the stopping power of the phantom materials must closely match
that of the tissue it is replacing for the dosimetric measurements to be meaningful. Deviations
in these properties between the phantom and tissue would lead to different radiation interac-
tions, resulting in a measured dose that has limitations for comparisons between the phantom
and patients. The phantom was designed to have tissue substitutes for breast and lung. The
tissue substitutes used were selected based on their similar absorption and scatter properties
as their tissue counterparts [53].
Considering both physical and dosimetric properties, the most commonly used breast tissue
substitute according to literature is wax [54]–[56]. The relative physical density of wax to water
is 0.94, which approximately corresponds to that of breast tissue taking into account both glan-
dular and adipose tissues of the breast [53]. Wax was consequently used as the breast tissue
substitute.
Chang et al. investigated and compared the physical properties of natural cork, composition
cork, rubber cork and the reference lung material (ICRU-44 lung tissue) [35]. The physical
properties investigated were physical density, electron density and effective atomic number.
Chang et al. found that the physical properties and dosimetry properties of composition cork
was the most similar to the ICRU-44 lung tissue. Composition cork was therefore used as the
lung-tissue substitute for the breast-lung phantom.
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Phantom Morphology
The size and shape of the phantom was designed to mimic breast and lung. However, the ma-
terials proposed above for simulating breast and lung tissue were more rigid than their tissue
counterparts. While this difference did not simulate the exact treatment conditions as if it were
a patient, the relative increase in rigidity of the phantom served as an advantage as phantom
positioning during the acquisition of the measurements were more reproducible [55].
Figure 4.1 shows the phantom design in side and birds eye views. The white region represents
the breast tissue and the orange region represents the lung. The blue horizontal lines indicated
in Figure 4.1a show slabs of wax making up the breast tissue. The black cross seen in Figure
4.1b represents the isocentric treatment position and the blue crosses seen in Figure 4.1b show
the lateral and longitudinal shifts of magnitude±0.5 cm,±1.0 cm and±2.0 cm to be performed
to simulate patient shifts on treatment. Vertical shifts of ±0.5 cm, ±1.0 cm and ±2.0 cm were
also implemented but are not diagrammatically shown.
(a) Side view (b) Birds eye view
FIGURE 4.1: Different views of the breast-Lung phantom
Figure 4.3a shows the breast-lung phantom design for measurements using an IC. As seen
in this figure, there were three slabs of wax representing the breast. The middle slab had an
insert in which the IC was placed for measurement during treatment delivery. The IC insert
was designed specifically for a CC13 IC shown in Figure 4.2. The dimensions of this chamber
were taken into consideration to minimise the air gaps within the cavity with the chamber
in place. The introduction of air gaps would alter the dosimetry and consequently affect the
dose measurement. Therefore this insert was only suitable for use with a CC13 chamber (iba
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FIGURE 4.2: CC13 IC used for dosimetric measurements
Dosimetry, Germany). For measurement of dose using radiochromic film, the middle slab was
replaced with two smaller slabs that can be separated at the indicated dashed line shown in
Figure 4.3b. For measurement of the EPID image, the middle slab was replaced by a solid wax
slab. Therefore, in addition to the top and bottom slabs a total of four middle slabs were made:
• One solid middle slab for EPID image acquisition.
• One middle slab with IC insert.
• Two middle slabs that can be separated at the reference depth and sum to the equivalent
thickness of the other middle slabs for film measurement.
The breast size of the phantom from the base of the breast to the breast apex (as shown in Fig-
ure 4.4) was 4.5 cm. The dimensions of the breast phantom were based on the average breast
dimensions of patients from the retrospective study. The depth of the DRP was based on the
average depth of DRP for patients from the retrospective study. The DRP was placed cen-
trally at a depth of 2.2 cm from the breast apex. The placement of DRP was checked to ensure
appropriate placement to minimise the uncertainties associated with both the measured and
calculated doses.
The dimensions of the phantom are shown in table 4.1 and Figures 4.4a and 4.4b. The three
versions of the phantom are shown in Figure 4.5.
TABLE 4.1: Breast-Lung phantom dimensions
Phantom Dimensions
Breast Size 4.5 cm
Reference depth 2.2 cm
Top 1.5 cm
Middle 1.5 cmSlab Dimensions
Bottom 1.5 cm
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(a) Placement of IC (b) Film placement
FIGURE 4.3: Breast-Lung Phantom Design
(a) EPID phantom (b) Film phantom
FIGURE 4.4: Phantom dimensions. Note: This figure is not to scale, the breast geometry
has been emphasised to show more details regarding the dimension of breast portion of
the phantom
(a) EPID phantom (b) IC phantom (c) Film phantom
FIGURE 4.5: Breast-Lung Phantom used for validation measurements.
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4.2 Methods
The breast-lung phantom will serve as an end-to-end test for reliable clinical use of EPIgray for
IVD of 3DCRT breast treatments. The entire treatment process was performed on the breast-
lung phantom.
CT simulation was performed on the phantom positioned using the CT lasers as shown in Fig-
ure 4.6. The overhead lasers were set to the centre of the phantom and the lateral lasers were set
to be coincident on the breast-lung interface. A typical patient would receive a skin reference
tattoo at the laser incidence on their skin however, there was no need for the placement of a
reference mark as the treatment position of the phantom already corresponded to specific and
reproducible points.
FIGURE 4.6: Setup of Breast-Lung phantom aligned to the lasers at CT simulation
The acquired CT simulation images were imported into Monaco version 5.1 (Elekta CMS,
Maryland Heights, MO, USA), the TPS employed at Christchurch Hospital. The treatment
was planned in a similar manner to an actual 3DCRT breast patient except with varied gantry
angles. Different gantry angles were employed to isolate and quantify the effects of lateral,
longitudinal and vertical shifts. The treatment plan consisted of two beams (treatment fields)
each delivering 1 Gy from linac gantry angles of 90◦ and 270◦. Figure 4.7 shows a CT slice of
the phantom on the treatment couch. This figure shows the two opposing beams from linac
gantry angles of 90◦ and 270◦.
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FIGURE 4.7: Treatment Plan of Breast-Lung Phantom
The dose to the DRP per fraction can be obtained from the TPS. This dose will be used to
draw comparisons between the EPIgray reconstructed doses as well as the doses that will be
measured using the IC and the film.
4.2.1 Film Calibration for Dosimetric Measurements
To obtain absolute dosimetric measurements from the radiochromic film, proper calibration of
the film is required. In order to achieve consistency in the film measurements and to minimise
the uncertainties associated with using a film scanner for dose readout, specific recommended
protocols were followed. The protocols used were taken from literature and were adjusted ac-
cordingly for this specific application [57]–[61].
FilmQAPro software (Ashland Inc., Covington, Kentucky, USA) was used to perform triple-
channel dosimetry using EBT3 GAFchromic film (Ashland Inc., Covington, Kentucky, USA).
EBT3 film type can provide absolute dose for dose ranges between 0.2 Gy and 10 Gy. FilmQAPro
allows dose measurement result comparisons from three colour channels, red, blue and green.
Given that the calibration protocols are correctly followed, the radiochromic film would con-
vert the measurement to absolute dose.
In order to perform an absolute dose measurements using the GAFchromic film, a calibration
curve for the specific batch of radiochromic film must first be established within the FilmQAPro
software. The method followed for establishing such a curve was based on previous rec-
ommendations and published results of the medical physics community. Publications have
demonstrated that if the protocols are closely followed, the uncertainties associated with the
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dose measurements should be within ±2.0% [60].
The film calibration procedure is outlined below:
1. Nine 3 cm strips were cut using a film cutter.
2. Eight strips were exposed to known radiation doses shown in table 4.2.
3. Irradiated strips were then scanned using the 48-bit flatbed Epson 10000XL film scanner.
4. The dose delivered to each calibration strip was specified within the FilmQAPro software.
5. The FilmQAPro software registered the red, blue and green channel values for these film
strips and provided the calibration curve for the particular batch of film that was used for
dosimetric measurements in this study.
TABLE 4.2: Doses delivered to the calibration film strips
Doses Delivered To Calibration Film Strips










Note, although the calibration curve would be valid for doses up to the highest dose deliv-
ered to the calibration film strips, it was recommended in literature that at least two strips
receive doses that are equal to or greater than the highest dose to be measured. Additionally,
FilmQAPro software makes a recommendation of selecting doses to provide an asymptotic fit
and to also have a strip that receives zero dose. Therefore the doses delivered to calibration
strips increased in geometric progression i.e. x, dX, d2X, d3X and etc. The calibration curve
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FIGURE 4.8: Calibration curve established for GAFchromic film used for dosimetric measurements
established for the batch of films used for dosimetric measurements is shown in Figure 4.8.
The treatment for the breast-lung phantom was planned to deliver a total fractional dose of 2
Gy. As per literature recommendations, the red channel dose calibration was used for dosi-
metric analysis [60], [61]. Figure 4.8 facilitates that the red channel had the most pronounced
change in the optical density measured by the scanner for the dose output of 2 Gy. Therefore us-
ing the the red channel dose values minimised the uncertainties associated with the measured
doses.
4.2.2 Simulation of Patient Setup Errors
Expected Treatment Position
The breast-lung phantom was setup on treatment at the expected treatment position using the
treatment room lasers. The middle wax slab of the breast was replaced with the corresponding
insert suitable for the type of measurement to be acquired. Dosimetric measurements were
acquired using an IC, film and EPID to calculate the dose delivered to the phantom.
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Offset Treatment Position Measurement
The phantom was intentionally offset from the expected treatment position by a known mag-
nitude to simulate patient setup errors on treatment. The phantom was offset in the lateral
(patient left to right), longitudinal (patient head to toe) and vertical (patient anterior to pos-
terior) planes by ±0.5 cm, ±1.0 cm and ±2.0 cm. These shifts were implemented using the
treatment couch which had a calibrated digital read-out indicating the couch position and con-
sequently the phantom position. The systematic setup error of the treatment couch was ±0.5
mm [62]. Additionally the lasers present in the treatment bunker were also used to verify the
shift magnitude.
4.2.3 Effect of Patient Setup Errors on the Percentage Dose Differences Provided
by Different Dose Verification Methods
The EPID images acquired for dosimetric analysis at the expected treatment position and offset
positions were used to calculate the fractional %DDDRP and %DDvol to analyse the effects of
patient setup errors on the %DD provided by the different dosimetric analysis methods avail-
able.
4.3 Results
The results section of the phantom study will be presented in two parts:
• Subsection 4.3.1 presents the doses measured and calculated at the DRP using the IC, film
and EPIgray at the expected and offset treatment positions.
• Subsection 4.3.2 presents the resulting fractional %DDDRP and %DDvol at the expected
and offset treatment positions.
4.3.1 Dosimetric Results at Expected and Offset Treatment Positions
Expected Treatment Position
At the expected treatment position the TPS predicted a dose of 2.008 Gy to the DRP. The doses
acquired using EPIgray, IC and radiochromic film at the expected treatment position are shown
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in table 4.3.
TABLE 4.3: Doses measured at expected treatment position by different dosimeters
Dosimeter Measured Dose (Gy) %DD from TPS (%)
IC 2.001 ± 0.000 -0.35 ± 0.00%
Film 2.001 ± 0.060 -0.35 ± 0.06 %
EPIgray 2.001 ± 0.070 -0.35 ± 0.07%
Table 4.3 shows strong agreement between the doses acquired using different dosimetric sys-
tems. All dosimetry systems indicated minor deviations between the planned treatment and
delivered treatment. This result indicates that at the expected treatment position, the EPIgray
dose was consistent with the doses measured by other dosimeters.
Whilst the accuracy of the average dose calculated using different dosimeters were equivalent
at the expected treatment position, the standard deviation associated with these measurements
indicate IC measurements to be the most precise, followed by film and lastly EPIgray. These re-
sults therefore show a higher variability associated with EPIgray doses than the other dosime-
ters. However, results from this section indicate that EPIgray reconstructed doses at the DRP
can be reliably used for verification of treatment delivery accuracy.
Offset Treatment Positions
Lateral Offsets
Figure 4.9 shows the %DDDRP measured using different dosemeters for lateral offsets. For all
positional shifts, the IC measurements have indicated an underdose to the DRP. The absolute
magnitude of the IC %DDDRP increased with increasing magnitude of positional shift. Shifts of
equal magnitude and opposite directions provided comparable %DDDRP. For positional shifts
of ±0.5 cm film measurements suggested an underdosing to the DRP. However, this result is
within the expected uncertainty and therefore whether the dose registered was an overdose or
an underdose was not of significance. For other positional shifts, film measurements have in-
dicated an overdose to the DRP. The EPIgray %DDDRP have indicated an overdose to the DRP
for all positional shifts. EPIgray also has the largest magnitude of %DDDRP for all positional
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shifts in comparison to other dosimetric systems. Unlike other dosimetric systems however,
the absolute magnitude of %DDDRP indicated by EPIgray does not increase in magnitude with
increasing magnitude of shift.
FIGURE 4.9: Dose measured by different dosemeters for lateral offsets
IC are routinely used for absolute point dose measurements. The geometry of these chambers
allow accurate point dose measurements [63]. The uncertainties associated with IC measure-
ments are smaller in comparison to the uncertainties associated with the film measurements
[22]. Therefore the IC measurements for each positional shift was used as the benchmark to
draw comparisons to EPIgray measurements. The difference between the IC %DDDRP and the
EPIgray %DDDRP is also shown in Figure 4.9. It is evident that at any given shifted position, the
absolute EPIgray %DDDRP was noticeably larger than the %DDDRP at the expected treatment
position. However, the changes in the %DDDRP with shifts of differing magnitudes were not as
pronounced for EPIgray as they were with IC measurements. This result indicates that EPIgray
was able to indicate a shift from the expected treatment position however, the magnitude of the
shift that had occurred in the lateral direction was not reflected in the calculated %DDDRP.
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Longitudinal Offsets
Figure 4.10 shows the %DDDRP measured using different dosimeters following positional shifts
of the phantom in the longitudinal plane. The longitudinal shift results were similar to the
results of the lateral shift. The IC doses consistently provided a %DDDRP that indicated an
underdose. The IC %DDDRP also demonstrated that with increasing magnitude of setup error,
regardless of the shift direction the absolute magnitude of %DDDRP would increase. For all
positional offsets, the film measurements have indicated an overdose to the DRP. The EPIgray
measurements indicated a noticeable increase in the absolute magnitude of %DDDRP with lon-
gitudinal positional offsets from the expected treatment position. The EPIgray %DDDRP for
positional offsets do not mirror the trend seen for other dosimeters. EPIgray results have
indicated that with increasing magnitude of offset from the expected treatment position, the
%DDDRP generally decreased. While this result was not expected, it may be explained by a
range of uncertainties associated with the EPIgray dose reconstruction. Inherent uncertainties
associated with the EPIgray dose reconstruction including variations in treatment parameters,
acceptable setup errors, and the uncertainties associated with the linac on the day of treatment
are a few factors that largely influence the EPIgray reconstructed doses. The influence of these
factors on the %DDDRP will be addressed in Chapter 5.
FIGURE 4.10: Dose measured by different dosemeters for longitudinal offsets
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Vertical Offsets
The resulting %DDDRP of different dosimeters following vertical positional offsets of the phan-
tom are shown in Figure 4.11. From Figure 4.11 it is evident that the IC consistently indicated
an underdose at all shifted positions. This observation for IC was consistent with the resulting
%DDDRP for setup errors of the phantom in other planes. Film %DDDRP generally indicated
an overdose to the DRP. Film %DDDRP results were consistent with %DDDRP results of setup
errors in other planes, i.e. at any given position from the expected treatment position resulted
in a noticeable increase in the %DDDRP. The resulting EPIgray %DDDRP with vertical offsets
mainly indicated an overdose trend with an underdose only occurring for a vertical downward
shift of 2 cm. In comparing the EPIgray %DDDRP with IC %DDDRP for vertical offsets, it was
evident that EPIgray consistently indicated a larger delivered dose to the DRP than intended.
The exception to this observation was seen with a vertical downward shift of 2 cm. EPIgray
calculated a -48.0% decrease in dose from the expected dose while the IC measured a %DDDRP
of -21.8%. The overshooting of the EPIgray %DDDRP with a downward shift of 2 cm is ex-
plained by EPIgray dose reconstruction algorithm’s difficulties in calculating dose to a point
with highly variable densities in the reconstruction field of view. The noticeable increase in
the magnitude of %DDDRP can be attributed to the differences in the way the TPS and EPIgray
handle heterogeneities in dose calculations. This finding is consistent with literature [64].
In comparing the IC %DDDRP to the EPIgray %DDDRP for positional shifts, with the exception
of downward 2 cm shift, it was found that EPIgray %DDDRP was typically approximately 2%
higher than the %DDDRP given by the IC measurements.
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FIGURE 4.11: Dose measured by different dosemeters for vertical offsets
4.3.2 Effect of Patient Setup Errors on %DDDRP and %DDvol
The fractional %DDDRP and %DDvol before and after positional correction on EPIgray analysed
using the DRP method and the volume method is presented in this section.
Figure 4.12 and Figure 4.13 show the %DDDRP and %DDvol for lateral positional offsets before
and after positional correction within EPIgray 1. From these figures, it is found that the %DDvol
was larger than %DDDRP both before and after positional correction. The standard deviation
associated with the %DDvol was found to be the smallest at the expected treatment position.
The standard deviation associated with the %DDDRP at each positional offset was found to de-
crease following positional correction.
1Figures showing the effects of positional correction (before and after) on %DDDRP and %DDvol were intention-
ally not combined. The scales of these graphs are different and therefore combining these figures will affect the
interpretation.
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FIGURE 4.12: Fractional %DD of lateral shifts before positional correction using refer-
ence and mean volume dose method
FIGURE 4.13: Fractional %DD of lateral shifts following positional correction using ref-
erence and mean volume dose method
In considering the effects of longitudinal shifts, using Figure 4.14 and Figure 4.15 it was found
that at each positional offset the %DDvol was larger than the %DDDRP. Additionally it was
found that with increasing magnitude of shift, the uncertainty associated with the %DDvol also
increased. The increasing uncertainty of %DDvol with positional offset was a result of EPIgray
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performing a dose calculation with increased amount of heterogeneties in the field of recon-
struction. The large standard deviation with these measurements can immediately alert the
treatment professional that an unexpected event has occurred and positional verification within
the EPIgray will need to be performed. With positional correction within EPIgray, the %DDvol
still remained larger in magnitude for every positional shift in comparison to %DDDRP. Follow-
ing positional correction, the magnitude of %DDDRP and %DDvol both decreased. Furthermore
it was found that the uncertainty associated with %DDvol at each phantom position has also
noticeably decreased. The standard deviation associated with each positional offset is similar
in magnitude regardless of the magnitude of offset. This finding emphasises the limitations of
EPIgray in reconstructing dose with highly varying densities in the field of reconstruction. The
smallest magnitude of %DDvol uncertainty was at the expected treatment position.
FIGURE 4.14: Fractional %DD of longitudinal shifts before positional correction using
reference and mean volume dose method
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FIGURE 4.15: Fractional %DD of longitudinal shifts following positional correction us-
ing reference and mean volume dose method
In considering vertical shifts, Figures 4.16 and 4.17 indicate that of all positional offsets, the
most significant changes to the %DD was seen with vertical shifts. The absolute magnitude
of %DDvol for vertical shifts was mostly found to be the greater than %DDDRP both before
and after positional correction within EPIgray. The standard deviation associated with %DDvol
measurements at each position increased with increasing magnitude of offset as expected. Fol-
lowing positional correction, the uncertainty associated with the %DDvol decreased for all po-
sitional offsets with the exception of downward shifts of 1.0 and 2.0 cm.
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FIGURE 4.16: Fractional %DD of vertical shifts before positional correction using reference
and mean volume dose method
FIGURE 4.17: Fractional %DD of vertical shifts following positional correction using
reference and mean volume dose method
82 Chapter 4. Phantom Study
4.4 Discussion
The results of the phantom study will be discussed in two parts. Subsection 4.4.1 will address
the effects of positional offsets on the EPIgray reconstructed doses and how EPIgray doses
compared to doses acquired using an IC and film. Subsection 4.4.2 will address the similarities
and differences between %DDDRP and %DDvol with phantom positional offsets to verify the
recommended clinical tolerance for %DDvol .
4.4.1 EPIgray vs. Established Dosimeters
Expected Treatment Position
The dosimetric results obtained at the expected treatment position revealed that the accuracy
of EPIgray doses were comparable to the doses acquired using other dosimeters. However the
standard deviations associated with these measurements revealed EPIgray reconstructed doses
to have larger uncertainty than the routinely used clinical dosimeters. The doses shown in table
4.3 are the average doses measured and calculated across three irradiations. Except for dosi-
metric measurements using film, which required placement of an unirradiated film between
each irradiation, no changes were made to the setup. Therefore the uncertainty associated with
the EPIgray reconstructed doses was a consequence of the uncertainties associated with the
treatment and EPIgray itself. The effects of the treatment-related and EPIgray-related uncer-
tainties will be investigated and discussed in Chapter 5.
The dosimetric results obtained using EPIgray and other routinely used dosimeters provided
quantifiable evidence to reliably use EPIgray at the expected treatment position for 3DCRT
breast treatments following positional correction.
Lateral Positional Offsets
The %DDDRP provided by all dosimetry systems were expected to be smallest at the expected
treatment position as all calculations were made with the geometry associated with the ex-
pected treatment position, and thus was shown to be true for lateral shifts.
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An increase in the absolute magnitude of %DDDRP was expected with increasing magnitude
of shift from the expected treatment position. The dependency of %DDDRP on the shift mag-
nitude is based on the changes to the position of the point at which the dose was calculated.
With lateral shifts, the depth of the DRP is effectively shifted, changing the geometry of the
treatment. This difference in the phantom position would alter the scatter environment result-
ing in the delivery of a different dose to the DRP. The two fields of the treatment were planned
to be incident with the phantom from gantry 90◦ and 270◦. Therefore the lateral shifts that
were performed would result in the movement of the phantom towards one field and further
away from the other depending on the direction of shift, i.e. if the phantom was shifted in the
positive lateral direction the phantom would be moved closer to the field at 90◦ and further
away from the field at gantry 270◦ and a negative shift would have the opposite result. Dur-
ing treatment planning, the treatment planner would assign the required dose to the point of
interest, in this case the DRP. The TPS would then calculate the number of monitor units (MU)
required to achieve the assigned dose at the DRP. At Christchurch Hospital, the MU as deliv-
erable radiation quantities are usually defined as follows. 1 MU is equivalent to 1 cGy under
reference conditions of source-to-detector distance of 100 cm, 10 cm depth in water-equivalent
material, for a treatment field size of 10 x 10 cm [63]. The TPS uses beam models of the linac
to calculate the number of MU required to achieve a particular dose requested from the TPS
by the planner. However, the TPS calculations are dependent on the set geometry of the treat-
ment. That is, the TPS uses patient setup factors such as the distance between the patient and
the radiation source and the thickness of patient before the DRP. For the phantom treatment
plan, the expected treatment position has been setup such that the DRP within the phantom
sits in the middle of the lateral distance between 90◦ and 270◦. However, with positional offset
the phantom position relative to the field is shifted for both fields. This shift in the depth of the
DRP will result in a different dose to be deposited at the DRP. This concept is best explained
using Figure 4.18, which shows the percentage depth dose (PDD) curve for a typical 6 MV pho-
ton beam. The PDD curve shows the percentage of maximum dose deposited by a radiation
beam as a function of depth. Using Figure 4.18, an increase or decrease in depth would alter
the dose to the DRP. Therefore with larger magnitude of shift, the %DDDRP from the TPS cal-
culated dose would be greater.
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FIGURE 4.18: 6 MV Percentage Depth Dose
The increase in the absolute magnitude of %DDDRP with increasing magnitude of shift was
seen for IC and film measurements but not with EPIgray. This finding suggests that while
EPIgray is capable of identifying that a treatment setup error has occurred by a noticeable in-
crease in the %DDDRP, the magnitude of EPIgray %DDDRP does not indicate the magnitude
of setup error. A setup error of ±2.0 cm is highly unlikely and patients will be setup again to
correct for this error if it is noticed on treatment. However, evidence from this section of the
investigation has revealed that the %DDDRP at ±2.0 cm are still within the tolerance of ±5.0%.
These results therefore highlight the importance of either establishing a process to double check
patient positioning on treatment or establishing a more sensitive %DDDRP tolerance for posi-
tional correction within EPIgray to account for setup errors as a clinically significant setup error
still produces an acceptable %DDDRP.
It was also expected that %DDDRP obtained for shifts of equal magnitude but opposite direc-
tions should be comparable, i.e. the IC %DDDRP at the 0.5 cm offset should be comparable to
the IC %DDDRP at the -0.5 cm offset. Both fields of the treatment plan had equal weighting in
terms of dose delivered to the DRP and therefore the effects of positive phantom shift should
be comparable to negative phantom shifts. Subject to minor variations, all three dosimetric
systems exhibited this trend. This finding implies that the EPIgray dose calculation algorithm
is not biased towards proximal and distal shifts of the patient.
Longitudinal Positional Offsets
Figure 4.19 shows the extent to which both fields of the treatment plan extend. The treatment
4.4. Discussion 85
fields are shown to extend 1.75 cm beyond the phantom surface. Fields extending beyond the
patient surface are often seen in radiotherapy plans that treat to the surface to ensure target
movement associated with patient breathing motion and patient setup errors on treatment do
not result in missing superficial part of the target volume. Flash allows the treatment to proceed
with the planned fields as the target volume will still be sufficiently irradiated. In considering
the magnitude of positional offsets performed on the phantom with reference to Figure 4.19,
the offsets of greater than 1.75 cm would provide a pronounced effect on the %DDDRP. There-
fore the longitudinal shifts of 2.0 cm regardless of whether it is a positive or negative shift
would result in the largest %DDDRP. With a shift of 2.0 cm in the longitudinal direction, the
treatment field would no longer be covering the entire phantom. Consequently there would be
less scatter than expected by the TPS for the original treatment position leading to a lower dose
calculated at the DRP.
FIGURE 4.19: Sagittal view: Extended beam fields to account for patient movement
By observation of Figure 4.10 the results of the IC were the most consistent with the expected re-
sult. Film and EPIgray both revealed overdoses across the positional offsets with the %DDDRP
increasing with magnitude of shift. These results are consistent with the results of the lateral
shifts. A systematic offset was seen between the IC doses and EPIgray doses. The overdoses
indicated by EPIgray were not actual overdoses but needed to be systematically offset to be
consistent with the results of the IC.
Considering only the EPIgray results, it was generally found that the %DDDRP from the TPS
decreased with increasing magnitude of shift. The %DDDRP was not expected to change sig-
nificantly for offset magnitudes of 0.5 cm and 1.0 cm regardless of the shift direction. However
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the largest impact on the %DDDRP was expected for the 2.0 cm offsets. With a positional shift
of greater than the magnitude of field extent, the decrease in the scatter from the portion of the
phantom that was missed by treatment field should have resulted in a lower dose than calcu-
lated at the DRP. This decrease in dose combined with EPIgray’s tendency to calculate a larger
dose to the DRP resulted in the dose to the DRP at ±2 cm being smaller than the doses of other
positional offsets of smaller magnitude. The variations seen across the other four longitudinal
offsets were within the EPIgray dose calculation uncertainties. These results highlight the oc-
currence of false results as a consequence of EPIgray-related uncertainties. Consequently the
results of this section provided clinical indication for verification of patient positioning within
EPIgray. If the fields of the treatment were sufficiently symmetrical with reasonable field ex-
tension such as the ones used in this investigation, the DRP may have received an acceptable
dose to the DRP however, the overall target coverage may be compromised if %DDDRP was
used without EPIgray positional correction.
Similar to the results of the lateral offsets, the resulting EPIgray %DDDRP did not provide any
indication of the magnitude of shift that had occurred. Small shifts such as the ±0.5 cm shifts
did not significantly impact the treatment outcome, however larger positional errors had the
potential to compromise the treatment. The EPIgray %DDDRP was within the ±5.0% tolerance
for larger positional offsets as seen in this section of the study. However the target coverage
was significantly reduced. Consequently the results from the lateral and longitudinal shifts
had indicated the need to verify the position of the patient within EPIgray to ensure that the
treatment was delivered as expected and the provided EPIgray %DDDRP could be reliably used.
Vertical Positional Offsets
Upward movements of the phantom result in more of the cork in the field. Consequently, the
cork which had a lower density than wax should have resulted in decreased scatter leading to
a lower measured dose for all dosimetric systems relative to the TPS predicted dose. However
there was sufficient flash in the field and therefore an upward shift of <2 cm should also not
have drastically affected the %DDDRP. For all vertically upward shifts of the phantom, the re-
sulting %DDDRP obtained using different dosimeters produced expected results. These results
have provided evidence that EPIgray %DDDRP could be reliably used for setup errors within
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the magnitude of the flash available in the plane perpendicular to the source.
In contrast, a downward movement of the phantom would result in more air occupying the
field and less cork. The flash only extends in the anterior direction. Therefore with a down-
ward shift corresponding to the movement of the phantom in the posterior direction, there was
a significant decrease in the scatter from the anterior direction leading to a significant decrease
in dose to the DRP. It was expected that with increasing magnitude of shift in the downward
direction, the magnitude of %DDDRP should decrease due to reduced dose from a lack of scat-
ter. This expected result was evident across all dosimeters. Figure 4.11 shows that downward
phantom movement of 2.0 cm resulted in the greatest deviation from the predicted TPS dose
for all dosimeters.
By comparing the IC measurements with the EPIgray measurements, it was found that the
EPIgray %DDDRP and IC %DDDRP were consistently within 2.5% for all longitudinal and lat-
eral shifts. In considering the vertical shifts, it was found that EPIgray %DDDRP was consistent
with IC %DDDRP granted that the field of reconstruction did not have largely varying tissue
densities. With downward movement of the phantom, there was a noticeable change in den-
sity as air would occupy the volume that was previously occupied by cork and wax on the cap-
tured EPID image. For downward movement of 2.0 cm the %DDDRP difference between IC and
EPIgray was 26.2%. This result indicated that EPIgray was capable of providing a %DDDRP that
would alert the treatment professional to a potential error that may have occurred, although
the magnitude of the %DDDRP was not entirely proportional with the shift magnitude that had
occurred.
4.4.2 DRP Dose vs. Mean Volume Dose
Investigation of the effect setup errors on treatment had on %DDDRP and %DDvol suggested
that %DDDRP was consistently smaller in magnitude than %DDvol . The advantage of using
%DDvol for dosimetric analysis was that %DDvol provided an indication of the treatment deliv-
ery accuracy to a sensible volume and not to a single selected point. Additionally %DDvol was
provided with a standard deviation. Large uncertainties associated with the %DDvol could be
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used as an indicator of an unexpected treatment delivery. The use of DRP for dosimetric analy-
sis provided a different set of advantages in that although the dose was only reconstructed to a
single point, this point was appropriately chosen such that the uncertainties associated with the
%DDDRP were minimised. Secondly, the investigation of potential errors was made easier with
the DRP analysis because the dose to the DRP was known within the TPS and could be simu-
lated at different points within the TPS if necessary. This was not an option with the %DDvol
because the 50 points are randomly selected by EPIgray and the position of these points are not
directly transferable to the TPS.
The trend of %DDDRP and %DDvol with clinically appropriate positional shifts were found to
be similar. The dose offset seen between both %DDDRP and %DDvol were not directly compa-
rable as one %DD was to a single point and the other considered multiple points. Results of
this section of the phantom study indicated that it would be clinically beneficial to have both
%DDDRP and %DDvol in place and not one over the other for the reasons mentioned above.
With the exception of a downward shift of 2 cm, it was found that following positional cor-
rection all positional shifted %DDvol were within ±5.0%. Considering that the %DDvol was
consistently larger than %DDDRP, the most conservative approach would be to set the frac-
tional %DDvol clinical tolerance to ±5.0%. Having a narrow tolerance placed on the %DDvol
would also aid in the reduction of false positive results. In considering the %DDDRP, the initial
tolerance of ±5.0% was retained based on the evidence from the retrospective study and the
phantom study. The %DDDRP analysis can be performed for each field, whilst the %DDvol only
considers the overall fraction. Therefore the use of %DDvol would be more sensitive to failures,
as this tolerance would take into account all the fields within each fraction. The standard devi-
ation associated with the mean reconstructed dose of the volume analysis should also be con-
sidered when using %DDvol as an indicator for treatment delivery accuracy. Fractional DDvol
exceeding the ±5.0% tolerance could be investigated using the dose to the DRP to identify the
specific field(s) that may have caused the failing result for the overall fraction. No significant
differences were found between breast lateralities and size and therefore this proposed change
is for all 3DCRT breast patients.
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4.5 Conclusion
The retrospective study confirmed that there was good agreement between the TPS doses and
the EPIgray reconstructed doses at the DRP. However validation was necessary to confirm that
the EPIgray reconstructed doses were representative of the doses delivered to the patient on
treatment. Results from subsection 4.3.1 reveal that there was a strong agreement between
the EPIgray reconstructed doses and the doses measured by other dosimeters at the expected
treatment position. While there were small differences between the TPS doses and the EPIgray
calculated doses, accurate EPIgray calculation of the dose was affected by a range of uncer-
tainties discussed in Chapter 5. These uncertainties may be minimised however could not be
eliminated altogether. The results section of this chapter had revealed that EPIgray could be
reliably used for in-vivo dosimetric verification of 3DCRT breast patients.
Results of the phantom study revealed that in the presence of phantom shift EPIgray consis-
tently calculated a dose that is larger than the doses measured using the IC and film. A range
of positional shifts were applied to the phantom to simulate patient setup errors. The greatest
shift applied in each direction was 2.0 cm. IC measurements were the most consistent with the
expected results based on the scatter and absorption properties. Additionally IC measurements
had the best agreement with the TPS and had the smallest uncertainties. Uncertainties for IC
measurements and film measurements were able to be reduced based on routine use of these
dosimeters clinically. The uncertainties associated with EPIgray doses will be explored in the
next chapter to be able to quantify and minimise these uncertainties. In drawing comparisons
between IC and EPIgray, it was evident that there was a positive offset in the calculated EPIgray
dose and IC measured doses for all offset positions. Across all planes and shifts in both direc-
tions, it was found that EPIgray %DDDRP was systematically offset by 2.5% with a downward
phantom shift of 2 cm being an exception. The phantom study provided further evidence of
EPIgray limitations with increasing amount of heterogeneities in the field of the dose recon-
struction. EPIgray provided a more pessimistic dose difference than what had occurred on
treatment. While EPIgray did not directly indicate the dose delivered, the pessimistic EPIgray
%DDDRP in comparison to the IC %DDDRP provided confidence that treatment accuracy was
achieved or would be more likely detected by the tolerance.
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Investigation of %DDDRP and %DDvol has revealed that the magnitude of %DDvol was con-
sistently larger than %DDDRP. Evidence from the retrospective study and the phantom study
indicated that a tolerance of ±5.0% placed on %DDvol was restrictive however effective. The
treatment fractions that fail to meet this tolerance could be analysed using the %DDDRP ±5.0%
tolerance. Based on the findings of the retrospective study and the phantom study, the ±5.0%
%DDDRP was retained. The primary reason for reducing this tolerance was to reduce the num-
ber of false passes. Whilst the tolerance on %DDDRP did not change based on the results of
this section, having %DDvol as another metric for dosimetric analysis of the treatment accuracy
with tighter tolerances would aid in limiting the number of false passes without significantly
changing the current clinical practice. Additionally the standard deviation associated with
mean reconstructed doses of the volume method was also shown to be a good indicator of
unexpected treatment events. Therefore the standard deviation associated with the mean re-
constructed dose should also be used as an indicator for treatment delivery accuracy.
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5 EPIgray Uncertainties
5.1 Factors Contributing to EPIgray Reconstructed Dose Uncertainty
The ±5.0% tolerance placed on the %DDDRP is the uncertainty associated with the EPIgray re-
constructed dose. The second objective of this project aims to decrease this tolerance to more
effectively identify unexpected treatment. The current tolerance was set based on measure-
ments acquired during commissioning of EPIgray. This tolerance is generic and applies to all
treatment sites. In order to decrease this tolerance specifically for 3DCRT breast treatments, the
factors contributing to this uncertainty must be identified and quantified.
The major factors that influence the magnitude of %DDDRP are discussed in the following sec-
tions:
1. Within 3DCRT breast treatments, treatment plan parameters are subject to vary from pa-
tient to patient depending on numerous factors including the patient’s anatomy. The
variations associated with these plan parameters affect the %DDDRP. Section 5.3 identi-
fies and quantifies the effects of 3DCRT breast treatment plan parameters and its effects
on the %DDDRP.
2. The setup of a patient on treatment will typically not be identical to the setup of the
patient at CT simulation. The presence of random errors associated with setup is always
present in a radiotherapy setting. Consequently radiotherapy treatments are planned to
minimise and account for these errors. As such the setup errors that may occur have
treatment tolerances. If the setup errors on treatment are within the given tolerances,
the treatment can proceed and is still considered to be effective treatment. Section 5.4
presents the differences in the setup of the patient and the EPID on treatment within the
acceptable tolerance and its corresponding effects on the %DDDRP.
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3. The EPIgray software itself provides an inherent uncertainty to the EPIgray reconstructed
dose based on the accuracy of the beam model under specific treatment parameters.
These EPIgray related factors contributing to the differences in %DDDRP are discussed
in section 5.5.
4. Lastly, the retrospective study has shown that positional correction within EPIgray af-
fects the magnitude of the %DDDRP. Positional correction involves the operator perform-
ing the correction to find the most appropriate alignment between the EPID and TPS
contours. Consequently variations in the matching between operators will result in dif-
ferences in %DDDRP. Section 5.6 will present the operator-related errors associated with
positional correction within EPIgray.
The purpose of this section of the study is to quantify the major factors causing deviations in
the EPIgray reconstructed doses. The findings of this chapter will determine the feasibility and
implications of decreasing the current ±5.0% tolerance for 3DCRT breast treatments.
5.2 Defining Uncertainties of Dosimetric Measurements
The uncertainties of dosimetric measurements like other measurements, are expressed with
reference to accuracy and precision. The precision of dosimetric measurements refers to the
reproducibility of the measurements in similar conditions. The precision of measurements can
therefore be estimated using the results of repeated measurements. The magnitude of the stan-
dard deviation of the measurements will provide an indication of the precision, where high
precision relates to a low standard deviation and vice versa. The accuracy of dosimetric mea-
surements refers to the closeness of the measured quantity to the true or expected quantity.
The inaccuracy associated with the measurement is referred to as the ’uncertainty’. The un-
certainties associated with measurements may be estimated using statistical methods (type A
uncertainties) or other methods (type B uncertainties).
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Type A Uncertainties
The best estimate for a dosimetric quantity D, would be the arithmetic mean for repeated mea-








The standard deviation for the set of repeated measurements quantifies the average uncertainty
of each individual measurement assuming gaussian variability. The standard deviation of the
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(D1 − D̄)2 (5.3)
Type A standard uncertainty (uA) is the standard deviation of the mean value (uA = σD̄). The
standard type A uncertainty can be evaluated using statistical analysis of repeated measure-
ments and the uncertainty associated with the dosimetric quantity is reduced with increasing
number of repeated measurements.
Type B Uncertainties
Type B standard uncertainty is not obtainable through repeated measurement. Rather, type B
standard uncertainty is determined through scientific judgement of non-statistical uncertainties
of the dosimetry quantity to be measured. Type B standard uncertainties include consequences
of the measurement process, use of literature defined physical data and application of correc-
tion factors to the measured quantity. The type B standard uncertainties is given as a fraction of
the limits beyond which there is no probability of occurrence. The chosen fraction is therefore
taken as the limits of the assumed distribution.
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Combined Uncertainty Of Dosimetric Measurements







M is the measurement given by the dosimetry system,
N is the number of repeated measurements,
Ci is the correction factor.
The dosimetric quantity therefore involves the combination of uA and uB uncertainties. The






The distribution of uC is assumed to be a normal distribution [14]. The product of uC and a
coverage factor (k) is used to obtain the expanded uncertainty, U, given in equation 5.6. A
coverage factor of 2, corresponds to 95% confidence level and is typically used to represent the
overall uncertainty.
U = kuC (5.6)
Therefore the dosimetric measurement will be expressed as DP ± U.
5.3 Treatment Parameter Uncertainties
Radiotherapy treatments are individualised to the patient. There are numerous treatment plan-
related factors that may differ from patient to patient and therefore it is important to quantify
the error contribution from each of these treatment parameters to determine an appropriate
5.3. Treatment Parameter Uncertainties 95
uncertainty tolerance. The major treatment plan parameters of 3DCRT breast treatments con-
tributing to the uncertainty associated with the EPIgray reconstructed dose are discussed be-
low.
Dose Linearity
An ideal IVD system should provide a response that is linearly proportional to dose. The EPID
images that were used as input for dose calculations using EPIgray were acquired using an aSi
EPID. Previous publications have identified non-linear dosimetric responses of the aSi EPID
[65]. Since doses of 3DCRT breast treatment fields are subject to variations, the relationship
between %DDDRP and dose was investigated.
Dose Rate Linearity
Radiotherapy treatments using linacs provide the capability of delivering the prescribed dose
faster or slower by adjustment of the dose-rate (MU/min). Increasing the dose rate will re-
sult in faster treatments and decrease the potential of patient movement during the treatment.
However, Winkler et al. have shown that the dose-rate affects the EPID response and conse-
quently the EPIgray reconstructed dose. The relationship between %DDDRP and dose rate was
investigated to quantify the uncertainties arising as a consequence of variable dose rate [65].
Gantry Angle
Gantry angles used for treatment of breast patients are subject to variations and are depen-
dent on the treatment laterality and the anatomy of the patient. The gantry angles of 3DCRT
breast treatments are specifically chosen to provide dose to the breast and to avoid dose to the
underlying lung tissue and contralateral breast. The variations in the %DDDRP with gantry
angles were investigated to quantify the error contribution arising from variable gantry angles
of 3DCRT breast treatments.
Source-Surface Distance (SSD)
The SSD is defined as the distance between the radiation source and the surface of the phan-
tom/patient. The SSD is subject to change between breast patients and is dependent on the
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breast size and the positioning on treatment. The effects of the expected range of SSD on the
EPIgray reconstructed doses were investigated to quantify the effects of SSD on the %DDDRP.
Field-size Dependency
The field sizes chosen for treatment are dependent on the patient anatomy. The larger the target
volume, the larger the field size. A wide range of breast sizes are seen in 3DCRT treatment of
the breast. Consequently, the fields employed to irradiate the target volume are also extensive.
Therefore it is important to identify the effects of field-size on the EPIgray reconstructed doses
and consequently the %DDDRP. The effect of field size on the %DDDRP was investigated using
a range of field sizes typically used for the treatment of 3DCRT breast patients.
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5.3.1 Methods
In order to investigate the effects of the factors mentioned above on the %DDDRP, a reference
plan was generated for a phantom with simple geometry. A stack of 30x30x15 cm3 solid water
was used for these measurements. Solid water was chosen as the phantom for this investiga-
tion because it is relatively water equivalent and therefore has similar scattering properties to
that of a patient. Additionally solid water is convenient for measurements because it can be
easily handled. The parameters of the reference plan for the stack of solid water are shown in
table 5.1.
The reference plan shown in table 5.1 was altered with different treatment parameters that have
the potential to cause deviations in the EPIgray reconstructed doses. Table 5.2 shows different
versions of the reference plan that were generated by changing a single treatment parameter
at a time to investigate their effects on the EPIgray reconstructed doses. The changes imple-
mented on each treatment parameter of the reference plan were based on the typical ranges
seen in 3DCRT breast treatments.
TABLE 5.1: Reference plan for treatment of solid
water
Treatment Plan Parameters Set Value
Gantry angle 0◦
Source-surface distance 90 cm
Dose 100 cGy
Dose rate 440 cGy/min
Field size 10 cm x 10 cm
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TABLE 5.2: Altered versions of the reference plan to investigate the effects of
these treatment parameters on the EPIgray dose reconstruction
Beam 2 Dose = 30 cGy
Beam 3 Dose = 63 cGy
Beam 4 Dose = 125 cGy
Beam 5 Dose = 250 cGy
Dose Linearity
(Changes to MU only)
Beam 6 Dose = 500 cGy
Beam 7 Dose-rate = 26 MU/min
Beam 8 Dose-rate = 53 MU/min
Beam 9 Dose-rate = 107 MU/min




Beam 11 Dose-rate = 440 MU/min
Beam 12 Field size = 9 cm x 5 cm
Beam 13 Field size = 9 cm x 10 cm
Beam 14 Field size = 9 cm x 15 cm




Beam 16 Field size = 20 cm x15 cm
Beam 17 SSD = 80 cm
Beam 18 SSD = 85 cm
Beam 19 SSD = 90 cm
Beam 20 SSD = 95 cm




Beam 22 SSD = 105 cm
Beam 23 Gantry Angle = 0◦
Beam 24 Gantry Angle = 30◦
Beam 25 Gantry Angle = 60◦
Beam 26 Gantry Angle = 90◦
Beam 27 Gantry Angle = 120◦
Beam 28 Gantry Angle = 150◦
Beam 29 Gantry Angle = 180◦
Beam 30 Gantry Angle = 210◦
Beam 31 Gantry Angle = 240◦
Beam 32 Gantry Angle = 270◦
Beam 33 Gantry Angle = 300◦
Gantry Angle Dependency
(Changes to gantry angle only)
Beam 34 Gantry Angle = 330◦
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5.3.2 Results
Dose To EPID Dependency
The results of the dose linearity investigation are shown in table 5.3. Figure 5.1 shows the rela-
tionship between %DDDRP and the TPS planned dose. The relationship between %DDDRP and
the dose delivered was shown to be non-linear. It was found that with an initial increase in
TPS dose, the %DDDRP increased rapidly. With further increase of the TPS dose, the %DDDRP
increased however, the increase in %DDDRP was less pronounced. As no other factors were
changed other than the dose delivered to the EPID, the results of this section have suggested
that the deviation in the %DDDRP was caused by a change in the EPID response to dose. This
result was consistent with other publications [65].










FIGURE 5.1: %DDDRP as a function of TPS planned dose
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Dose-Rate Dependency
The relationship between the %DDDRP and dose rate was investigated by using clinical dose
rates to determine the extent to which the accuracy of EPIgray dose reconstruction was affected
by the dose rate. The results in Figure 5.2 show the measurements normalised to the dose rate
of the reference plan. In considering the dependence of %DDDRP on the dose rate, it was found
that the accuracy of EPIgray reconstructed doses decreased with decreasing dose rates. The
increasing %DDDRP with decreasing dose rates could be explained by increasing noise over a
longer image acquisition period.
FIGURE 5.2: %DDDRP from TPS as a function of the dose rate
Gantry Angle Dependency
The %DDDRP for gantry angles ranging between 0° and 360° with 30° increments were mea-
sured and calculated using EPIgray. The resulting %DDDRP for these gantry angles were nor-
malised to the dose at 0° and are shown in Figure 5.3.
The gantry angle used for treatment would vary from patient to patient depending on patient
anatomy. The gantry of the linac weighs several tonnes and cannot be equally balanced. Conse-
quently the gantry is susceptible to different magnitudes of sag at different gantry angles under
the influence of gravity. The gantry sag would lead to the relative offset in EPID position from
the expected position. This would lead to the calculation of an inaccurate %DDDRP. Figure 5.3
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FIGURE 5.3: Effect of gantry angles on the %DDDRP from TPS
shows that the %DDDRP is dependent on the gantry angle. The inaccuracy of EPIgray recon-
structed doses noticeably increases at gantry 90° and 270°. For majority of the gantry angles
however, the %DDDRP remains within 1.5%.
SSD Dependency
SSD dependency was intended to check how EPIgray dose reconstruction would deal with
changes in patient thickness. Figure 5.4 shows the result of varying SSDs on the %DDDRP from
the TPS. The SSDs do not significantly vary for 3DCRT breast patients, however the extreme
upper and lower limits were investigated.
The %DDDRP of different SSDs shown in Figure 5.4 have been normalised to the dose at the 90
cm SSD of the reference plan. Figure 5.4 does not reveal an obvious trend between the SSD and
EPIgray accuracy. However, it is found that at extended SSDs, the EPIgray accuracy decreases
noticeably.
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FIGURE 5.4: Effect of SSD on the %DD from TPS
Field Size Dependency
The effect of field size on the %DDDRP from the TPS was investigated using field sizes that
are commonly seen in 3DCRT breast treatments. The results of this investigation are shown in
Figure 5.5.
The field size will affect the dose delivered to the point of interest. Delivering 100 MU and
changing the field size will result in delivering a different dose. Consequently in order to draw
comparisons between rectangular fields of different sizes, the concept of equivalent square field
(EQS) was employed. The EQS of a rectangular field will exhibit similar scattering properties.
Therefore to enable efficient analysis, the EQS was found for all field sizes considered in this
investigation. The EQS was found using equation 5.7. The resulting %DDDRP for each field





Where, a and b are the length and width of the rectangle. The x-axis of Figure 5.5 has been
labelled as EQS rather than the field sizes shown in table 5.2.
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FIGURE 5.5: Effect of field size on the %DDDRP from TPS
Figure 5.5 shows that the accuracy of EPIgray is affected by the field size. The absolute magni-
tude of %DDDRP increases with deviations from the reference EQS of 10 cm. Over the typical
field sizes of 3DCRT breast treatments, the %DDDRP is within ±1.0%.
5.3.3 Discussion
The results of the dose linearity investigation showed that the %DDDRP increased with in-
creasing dose. There was a non-linearity associated with %DDDRP with increasing dose. At
Christchurch Hospital, 3DCRT breast treatment fields are planned to deliver between 4 cGy
to 350 cGy [66]. The %DDDRP over this dose range was found to vary between 0.2% to 2.1%.
Ideally, the %DDDRP should not be dependent on dose however the results from this investi-
gation have suggested otherwise. Consequently, the clinical tolerance should account for this
dependency. The results of this section are consistent with literature. It is reported that up to
10% non-linearity can be expected with varying dose when using an aSi EPID for dosimetry
[65]. EPIgray at Christchurch Hospital has been commissioned with correction factors from
DOSIsoft to account for the non-linear response of the EPID to dose. While the corrections
have reduced the uncertainty associated with the EPID response to dose, the clinical tolerance
of %DDDRP must account for the remaining inaccuracy. Based on the results of this investi-
gation, an error contribution of ±2.0% is recommended to account for variations in the EPID
response with dose.
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Investigation of the %DDDRP dependency on the dose rate has revealed that the %DDDRP and
dose rate do not have a linear relationship. Ideally, %DDDRP should not depend on the dose
rate however it was found that with decreasing dose rate, the %DDDRP increased. With de-
creasing dose rate, the radiation delivery time increases. Therefore the decrease in EPIgray
accuracy associated with decreasing dose rate can be explained by an increase in the electrical
noise captured on the EPID image over a longer dose delivery period. Currently EPIgray does
not contain corrections for the effects of dose rate. However, the EPID dosimetric calibrations
and the linac modelling within EPIgray have been performed at the maximum dose rate and
all 3DCRT breast treatments at Christchurch Hospital are delivered with the maximum dose
rate and therefore significant corrections for the effect of dose rate are not necessary. However,
during treatment delivery the dose rate displayed on the console is subject to minor variations,
therefore an error contribution of ±0.1% is recommended to account for these variations.
The variations seen in the %DDDRP with gantry angles were expected. The greatest %DDDRP
from the TPS was seen at gantry 90° and 270°. This result was expected as the magnitude of
gantry and EPID sag were expected to be the greatest at these angles as a result of gravitational
forces. Changes in the distance between the EPID and the radiation source within the gantry
leads to different central pixels, which are perceived as an offset. Therefore the %DDDRP was
expected to differ between gantry angles. Additionally the variations seen in the %DDDRP
across different gantry angles may also be a result of beam obliquity. The TPS and EPIgray do
not employ the same dose calculation algorithms. Consequently, these dose calculation algo-
rithms may handle beam obliquity differently resulting in varying magnitudes of uncertain-
ties associated with the reconstructed dose depending on gantry angle. The clinical tolerance
for 3DCRT breast treatments will also need to account for the error associated with varying
gantry angles. The nature of 3DCRT treatments means that treatment fields should never be
delivered from the cardinal angles to avoid unnecessary dose to the OAR. Breast treatments
are planned using tangential fields that are specifically angled to provide dose to the breast
and avoid dosage to the underlying lungs and therefore the inaccuracies associated with the
EPIgray reconstructed doses at the cardinal angles will not be considered for the gantry angle
error contribution. An error contribution of±1.5% is recommended following consideration of
the clinically relevant treatment angles for 3DCRT breast treatments.
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Investigation of the SSD influence on EPIgray accuracy has revealed that %DDDRP was depen-
dent on the SSD to a small extent. The SSDs of the patients in the retrospective study ranged
between 85 cm to 97 cm. Over this range, the results have revealed %DDDRP to vary within
±0.2%. This error contribution encompasses majority of 3DCRT breast patients. SSDs greater
than 100 cm, classified as extended SSDs are not likely, however these SSDs were incorporated
into this investigation to gain understanding of the overall trend. It was found that with ex-
tended SSDs, there was a noticeable increase in the absolute magnitude of %DDDRP. However,
the SSD error contribution to EPIgray accuracy at extended SSDs is not clinically relevant for
breast patients. An error contribution of±0.2% is recommended following consideration of the
clinically relevant SSDs for 3DCRT breast treatments.
Results have revealed that %DDDRP was also dependent on field size as expected. With devia-
tions from the reference 10 cm x 10 cm field size, the absolute magnitude of %DDDRP increases.
The EQS range of the patients of the retrospective study was between 7.7 cm and 15.5 cm. Over
this EQS range, the %DDDRP varies by approximately 1.0%. In considering this range, a field
size error contribution of ±1.0 % is recommended.
5.4 Treatment Setup Errors
Minor setup errors associated with EPID and patient positioning on treatment are unavoidable.
This section will address the consequences and contribution of these random and systematic
errors on the %DDDRP.
EPID Positioning
The EPID on treatment is only extended into the image acquisition position when an EPID im-
age is required. The Elekta iViewGT EPID used in this study for acquisition of EPID images
has an isocentric position when deployed. The EPID will extend until the isocentric position
is reached and the movement of the EPID pauses for approximately 1 second to allow the ra-
diation therapist to identify the isocentric position. The radiation therapists may then shift the
panel to a different position if required. Potentiometers are used to identify the lateral and
longitudinal positions of the isocentre. The voltage of the potentiometers are compared with
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a known voltage that is set at calibration to identify the isocentre position [25]. The iViewGT
EPID on the Elekta linac does not have a system to indicate the EPID’s exact position in space.
The isocentric position voltage may drift and therefore, when the EPID is extended it may be at
a slightly different position from its previous extended position even if it is assumed to be at the
isocentric position. The retrospective study has indicated that EPID position has a significant
effect on the %DDDRP. Therefore the reproducibility of the panel position was investigated.
Acceptable Setup Errors
It is unlikely a radiotherapy treatment will be delivered exactly as intended due to random
and systematic errors associated with the treatment setup. The setup factors specific to 3DCRT
breast treatments that need to be considered are the gantry angle, SSD, field size, the patient
setup according to treatment couch positions and patient positioning e.g. rotations of the body
oriented towards the linac. 3DCRT treatments are planned to account for minor variations in
these factors and therefore there are acceptable tolerances for each of these factors on treatment.
The tolerances placed on these setup parameters at Christchurch Hospital are shown in table
5.4 [67].
TABLE 5.4: Acceptable setup tolerances for 3DCRT breast treatments
Parameter Tolerance Level
SSD ±1.0 cm
Gantry Angle ± 2.0°
Patient Setup ± 0.5 cm
Field Size ± 0.1 cm
The variable range associated with the acceptable setup errors will affect the magnitude of
%DDDRP and therefore the error contributions from these setup parameters were investigated.
5.4.1 Method
EPID Positioning Reproducibility Tests
In order to investigate the effect of minor variations in EPID position on the %DDDRP, the solid
water phantom and the reference plan shown in table 5.1 were employed. The solid water was
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setup at the expected treatment position. Without any additional changes to the setup, five
EPID images were acquired using the reference plan. The resulting EPID images were used to
acquire the reconstructed doses to the DRP and the corresponding %DDDRP. No changes were
implemented between each consecutive image acquisition. The average of these measurements
were used as the control for the analysis of the panel position reproducibility test.
Following acquisition of the control EPID images, the reference plan was delivered five more
times to acquire five additional EPID images. However for this set of measurements, the EPID
was folded away and back into acquisition position between each image acquisition. The re-
sulting averages of these two sets of EPID images provided the uncertainty associated with the
EPIgray reconstructed doses as a result of EPID positioning.
Contributions from Variations in Acceptable Setup Errors
Based on the acceptable tolerances on setup parameters shown in table 5.4, both the breast-
lung phantom and the solid water phantom were used to simulate the worst-case acceptable
treatment conditions to quantify the effects these factors have on the %DDDRP.
5.4.2 Results
EPID Positioning Reproducibility Tests
The EPIgray reconstructed doses and the corresponding %DDDRP of the control measurements
are shown in table 5.5.








1 98.00 98.75 0.77
2 98.00 98.77 0.79
3 98.00 98.75 0.77
4 98.00 98.76 0.78
5 98.00 98.80 0.82
Average 98.00 98.77 ± 0.05 0.78 ± 0.05
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Table 5.6 shows the resulting reconstructed doses and the corresponding %DDDRP of five EPID
images acquired during the EPID position reproducibility test in which the EPID was folded
away and back into acquisition position between each image acquisition. Comparisons of the
results in table 5.5 and table 5.6 reveal a difference between the average of controlled measure-
ments and the average of the EPID positioning reproducibility test measurements. The average
%DDDRP increased with EPID movement between consecutive image acquisitions. Addition-
ally, the associated standard deviations with these measurements also increased in the EPID
positional reproducibility test. A t-test assuming equal variance with a significance level of 5%
was consequently conducted with the null hypothesis that there were no statistical differences
between the two sets of measurements. The obtained p-value was 0.03. The p-value indicates
that there were statistical differences between the %DDDRP acquired with no EPID movement
between image acquisitions and the %DDDRP acquired with EPID movement between each
image acquisition.







1 98.00 99.07 1.09
2 98.00 99.08 1.10
3 98.00 98.85 0.87
4 98.00 98.84 0.86
5 98.00 98.79 0.81
Average 98.00 98.93 ± 0.05 0.94 ± 0.05
Acceptable Setup Errors On Treatment
Following simulation of acceptable setup errors on the breast-lung phantom and the solid wa-
ter phantom, it was found that the contributions from these setup errors were comparable
between both phantoms. The variations in the %DDDRP as a consequence of variations in the
acceptable setup errors are shown in table 5.7.
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The results of the panel position reproducibility test and subsequent comparison to the control
results have revealed that there were statistical differences between the %DDDRP acquired with
and without EPID movement between consecutive image acquisitions. The %DDDRP and the
associated uncertainty was found to be smaller in magnitude with no EPID movement between
each image acquisition. This result was expected and the results of this section have revealed
that the minor positional variations of the EPID in space does have a quantifiable impact on
the EPIgray provided %DDDRP . The consequences of panel movement between image ac-
quisitions were small positional changes of the EPID. Consequently the EPIgray reconstructed
doses were susceptible to slight variations with changes to the reconstruction environment and
these variations were reflected in the provided %DDDRP. The %DDDRP suggested by EPIgray
following EPID movement on average was 0.16% higher than the average %DDDRP with no
EPID movement. Based on these findings an error contribution of ±0.2% is recommended for
panel positioning reproducibility.
The results of this section have shown that the acceptable setup errors on treatment would
affect the accuracy of the EPIgray reconstructed dose. The error contributions of these factors
with the exception of patient setup were relatively small as expected. However, these error
contributions will need to be considered when determining the uncertainty associated with
the EPIgray reconstructed dose of breast treatments. The largest source of error was associated
with patient positioning. This result was expected because small random errors associated with
positioning are always present. The error contribution for patient setup was obtained from the
results of the phantom study found in subsection 4.3.1. Therefore these measurements were not
repeated in this section of the study. It must be noted that the setup errors investigated consider
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the dose to the DRP only and not to the entire target volume. Consequently, there may be areas
that are more significantly impacted as a consequence of these setup errors. Therefore there are
possibilities for these error contributions to be greater than the given magnitudes.
5.5 Inherent EPIgray Uncertainties
Inherent uncertainties associated with EPIgray is a consequence of two major factors. These
factors are errors associated with the linac modelling within EPIgray and EPID calibrations.
Linac Modelling Within EPIgray
Beam modelling of the linac within EPIgray was implemented by acquiring EPID images under
specific conditions comparable to the test performed in section 5.3 to examine the effect of field
size on the %DDDRP. The resulting EPID images were sent to DOSIsoft, and the beam model
library was consequently built from user data. DOSIsoft beam modelling produced deviations
within ±1.0% for phantom thicknesses ranging between 10 cm and 30 cm and for EQS rang-
ing from 5 cm to 20 cm. While the DOSIsoft provided %DDDRP exhibited a smaller influence
of field size on the %DDDRP, these results were based on the identical images that were used
for beam modelling. Therefore it was expected for these deviations to be noticeably smaller
than the measured results. During commissioning, DOSIsoft recommended that the deviation
between the delivered and the reconstructed dose be within ±2%. The EPIgray-related errors
established to be within ±2% by DOSIsoft also accounts for the EPID calibration deviations.
EPID Calibration
The EPIgray-related uncertainties are routinely checked as part of QA to ensure the magni-
tude of error remains within ±2.0% under calibration conditions. A calibration factor is used
to convert the pixels of the transmission image registered on the EPID to dose. EPID calibra-
tions are performed when maintenance work results in changes in the EPID response or when
the %DDDRP exceeds the EPIgray tolerance. If the %DDDRP exceeds ±2% without evidence of
setup errors, a drift in the EPID calibration is indicated and consequently an EPID calibration
is performed.
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EPID calibration involves the measurement of the output of the machine and acquisition of an
EPID image. The EPID image is subsequently imported into EPIgray and the pixel values of
the EPID image are related to the dose delivered to provide a calibration factor. The output
measurement of the linac and consequently the dose delivered to the EPID for calibration is
acquired using an IC. The primary source of uncertainty resulting from the EPID calibration
comes from using the IC for the output measurement. There are a number of factors that influ-
ence the uncertainty of an output measurement made using an IC. The main sources of error
for measurements acquired using an IC include the IC calibration error, the detector placement
error, the linac output variations on the day of measurements and the statistical type A error
associated with the measurements acquired.
IAEA TRS-398 has identified the combined standard uncertainty associated with dose to water
to be within ±1.5% [63]. The use of IC to measure the dose to a point of interest also requires a
range of correction factors outlined in IAEA TRS-398. These corrections factors are outside the
scope of this project however, do provide a small contribution of±0.1% to the total uncertainty
[63].
Measurement of the dosimetric output of the linac is subject to variations due to a range of
reasons including variations in pressure and temperature on the day of the measurement. A
clinical tolerance of ±0.5% is routinely used to account for these variations [68].
The active region of the IC in comparison to the field size is sufficiently small such that a rel-
atively large offset in the x or y directions would not significantly affect the dose measured.
However, the changes in the dose with shifts in the z direction (movement of the chamber to-
wards or away from the source) will need to be accounted for using the inverse square law
(ISL). Positional shifts in the z direction are highly unlikely however, for a positional shift of 1
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Following an audit of the output measurements of the linacs, type A measurement uncertainty
associated with repeated measurements were found to be ±0.2% for a routinely used and cali-
brated IC. A summary of the EPID calibration related error contributions is shown in table 5.8.
TABLE 5.8: Estimated magnitude of errors related to EPID calibration
Component Estimated Error Contribution
IC Calibration Error ±1.5%
Output Dosimetric Error ±0.5%
ISL ±0.2%
Type A Measurement Error ±0.2%
The recommended DOSIsoft EPIgray tolerance of ±2.0% accounts for inaccuracies resulting
from linac-modelling within EPIgray and EPID calibrations. These factors will contribute to
EPIgray reconstructed doses and therefore will need to be incorporated in the final calculation
to determine the uncertainty associated with EPIgray reconstructed doses of 3DCRT breast
treatments.
5.6 Operator Related Uncertainties
Following the acquisition of the EPID images on treatment, EPIgray automatically performs a
dose calculation to provide a %DDDRP for each field that was delivered to the patient. If this
%DDDRP for any field within the fraction exceeds the ±5.0% tolerance, positional correction is
performed within EPIgray to ensure that the %DDDRP provided is representative of the treat-
ment delivered to the patient. Consequently, the positional corrected %DDDRP provided by
EPIgray is dependent on the alignment between the TPS contours and patient contours evi-
dent on the EPID images. Frequently, perfect match between the contours is unattainable and
operator judgement is required for the most appropriate match. Therefore operator match-
ing judgement to a certain degree plays an important role in the reconstructed dose. In order
to quantify the effect of differential matching, seven physicists with variable experience with
EPIgray were asked to perform EPIgray corrections on three patients. Three patients were
selected based on the breast size seen on the EPID images as well as the laterality of their treat-
ment to investigate how these variables affect the inter-person matching. The patient numbers
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and the corresponding breast size and laterality are shown in table 5.9. The EPIgray correc-
tional analysis instructions given to the seven participants can be found in appendix A.
TABLE 5.9: Laterality and breast size of patients used for inter-person matching varia-
tions on EPIgray





Seven participants were asked to perform contour matching positional correction on EPIgray
for the three patients shown in table 5.9. Participants were asked to note the shifts in x and
y directions to attain the best possible alignment based on their judgement and the resulting
%DDDRP. The patients shown in table 5.9 were selected to draw conclusions regarding match-
ing for both breast lateralities and sizes. Comparisons of the correction results between patients
1 and 2 would reveal how the laterality of the treatment site would affect the matching results,
given that the size of breast are comparable and comparisons of the correction results between
patients 1 and 3 would reveal how breast size of the patient would affect the matching results
given that lateralities are the same for these patients.
5.6.2 Results
Differences in the positional shifts required between different breast groups
The results of positional correction conducted by each participant was analysed individually.
For each participant, a total of four paired t-tests were performed:
1. The magnitude of shifts required in the x-direction for all fields of patient 1 and patient 2
to determine differences in matching dependent on breast laterality.
2. The magnitude of shifts required in the x-direction for all fields of patient 1 and patient 3
to determine differences in matching dependent on breast size.
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3. The magnitude of shifts required in the y-direction for all fields of patient 1 and patient 2
to determine differences in matching dependent on breast laterality.
4. The magnitude of shifts required in the y-direction for all fields of patient 1 and patient 3
to determine differences in matching dependent on breast size.
The paired t-test used a significance level of 5% and assumed that the two data sets were not
significantly different and hypothesised a mean difference of 0. The obtained mean p-values
for these paired t-tests are shown in table 5.10.
TABLE 5.10: P-values of paired t-test conducted on the magnitude of shifts required as
determined by each matcher
x-direction y-direction
Operator
Left vs. Right Small vs. Large Left vs. Right Small vs. Large
1 0.45 0.69 0.92 0.12
2 0.57 0.79 0.37 0.16
3 0.55 0.73 0.55 0.2
4 0.08 0.39 0.75 0.07
5 0.33 0.06 0.51 0.06
6 0.62 0.67 0.7 0.37
7 0.24 0.64 0.5 0.15
Results of table 5.10 reveals that participants did not exhibit any bias in matching for both
breast groups. All p-values in table 5.10 are larger than 0.05 and therefore the null hypothesis
cannot be rejected as the resulting differences between the breast groups have a greater than
5.0% probability of occurring by chance.
Additionally, correlation analysis was conducted between the shifts required in the x and y di-
rections between participants. The correlation coefficient measures the strength and direction
of relationship between variables. Correlation analysis was performed for shifts in the x and
y direction separately. The variables of the correlation analysis in this setting were the shifts
required in each direction as determined by the seven participants. For both directional shifts,
the correlation analysis has revealed a moderate to strong relationship as indicated by the cor-
relation coefficient. Where, a moderate relationship is indicated by a correlation coefficient
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between -0.3 and -0.7 or 0.3 and 0.7 and a strong relationship is indicated by a correlation coef-
ficient between -0.7 and -1.0 or 0.7 and 1.0 [69]. This result indicates that there are no significant
variations in the shifts required as determined by different operators. The average correlation
coefficients obtained for each breast laterality and size revealed that right breast fields and large
breast fields had higher agreement between the shifts required in x and y directions than left
breast and small breast fields.
The resulting variation in the %DDDRP as a consequence of differences in positional correc-
tion between participants was also considered. Figures 5.6a and 5.6b show the variation in the
EPIgray %DDDRP from TPS following positional correction of left and right breast fields.
(a)
(b)
FIGURE 5.6: EPIgray %DDDRP following correctional analysis on
EPIgray for (a) left and (b) right breast fields.
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From Figures 5.6a and 5.6b it is visually evident that there is better agreement between the
operators in terms of %DDDRP for right breast fields than left breast fields. The magnitude of
EPIgray %DDDRP post-positional correction within EPIgray is not of concern in this section, as
the interest is primarily considering the grouping of %DDDRP. Correlation analysis revealed
moderate to strong relationship in the %DDDRP across all participants for left breast fields and
strong relationship in the %DDDRP across all participants for right breast fields. In considering
the average correlation coefficient of each group, it was found that right breast fields had more
agreement in %DDDRP than left breast fields.
Figures 5.7a and 5.7b show the variations in the EPIgray %DDDRP from TPS following posi-
tional correction on EPIgray of small and large breast fields.
(a)
(b)
FIGURE 5.7: EPIgray %DDDRP following correction analysis on EPIgray for (a) small
and (b) large breast fields.
5.6. Operator Related Uncertainties 117
From Figures 5.7a and 5.7b it is visually evident that there is better agreement between the
operators in terms of %DDDRP for large breast fields than small breast fields. While certain large
breast fields show similar levels of variations in the %DDDRP as a consequence of positional
correction, the variation was more pronounced with small breast fields than large breast fields.
Correlation analysis revealed strong correlation in the %DDDRP across all participants for both
breast size fields. However in considering the average correlation coefficient of each group, it
was found that large breast fields had more agreement in %DDDRP than small breast fields.
5.6.3 Discussion
The volunteers for this investigation were physicists with varying levels of EPIgray experience.
Positional correction conducted by these participants has revealed no significant differences
in terms of magnitude of shifts required between fields of different breast sizes and laterali-
ties. Participant feedback regarding positional correction on EPIgray has revealed consensus
amongst the participants that compromise is required when perfect positional alignment be-
tween the EPID image contours and TPS contours is unattainable. Operators were not given
specific instructions as to which regions they should compromise when matching. Therefore
the compromises the operators chose were entirely at their discretion. Additionally results of
this section indicate that there are no major discrepancies associated with the inter-operator
matching for breast groups when performing positional correction on EPIgray. This finding
provides evidence that the inter-operator matching error is minimal. Participants revealed that
compromises were made when performing contour matching with particular consideration
given to the position of the DRP. All participants, regardless of their experience with EPIgray
compromised mismatch between the TPS and EPID image contours in regions away from the
DRP. All participants paid particular attention at the level of the DRP when matching the con-
tours and compromises were made at other lesser important regions. Consequently operators
have identified that there was typically poor matching near the arm and axilla regions. These
results have indicated that the inter-operator variability associated with positional correction
on EPIgray is negligible granted that the matcher has sufficient experience with 3DCRT breast
treatment plans in order to determine which matching compromises are clinically appropriate.
118 Chapter 5. EPIgray Uncertainties
In considering the %DDDRP between fields of different breast lateralities, it was found that left
breast fields showed more of variation than right breast fields. This finding could be explained
by the increase in the heterogeneities seen in left breast fields. The right breast fields typically
have air, lung and breast tissue in the reconstruction environment. For left breast fields in
addition to air, lung and breast tissue, the presence of the heart is also seen in some fields.
Accuracy of EPIgray dose reconstruction algorithm with increasing density heterogeneities in
the field has been previously discussed. Therefore the range of %DDDRP seen for left breast
fields being larger than right breast fields of similar size is partially explained by the EPIgray
dose reconstruction algorithm itself. Similarly, in considering the %DDDRP between fields of
different breast sizes it was found that small breast fields showed more of variation than large
breast fields. This result was expected as minor shifts in the small breast fields would result in
a more drastic change in the environment over which the dose reconstruction is performed.
5.7 Proposed EPIgray Uncertainty Tolerance
Sections 5.3 to 5.6 have presented the major factors causing deviations in the EPIgray recon-
structed doses. These errors were combined in quadrature in accordance with the International
Bureau of Weights and Measures (BIPM) recommendations to provide the overall uncertainty
[70]. The total combined error is presented in table 5.11.
Table 5.11 reveals that the smallest achievable uncertainty associated with the EPIgray recon-
structed doses would be ±3.3%. The retrospective study has shown that fields exceeding
±5.0% following positional correction may still represent a dosimetrically accurate treatment
but are considered a failed result according to EPIgray due to the set tolerance. Fields that are
dosimetrically accurate but present as failing results occur as a result of two main reasons:
1. Inaccurate EPID image acquisition, and/or
2. The imposed±5.0% does not cover the entire range of patients seen in the clinical setting.
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TABLE 5.11: Estimated total magnitude of error associated with %DDDRP














Output Dosimetric Error ±0.5%
ISL ±0.2%
Inherent EPIgray Errors
Type A Measurement Error ±0.2%
Operator Related Errors ±0.0%
Total Combined Error ±3.3%
Due to these reasons and the results of this study, it is recommended that the ±5.0% tolerance
be retained. Increasing this tolerance may result in a larger number of falsely passing fields
passing through unnoticed. Decreasing this tolerance is also not appropriate as currently, fields
that exceed the current tolerance given no major errors have occurred are still considered dosi-
metrically accurate treatments.
Nevertheless, the current ±5.0% tolerance results in a significant number of false passes. In
order to reduce this number, the introduction of a new intervention tolerance is proposed. Cur-
rently the intervention tolerance and the passing tolerance are both ±5.0%. In order to find the
most appropriate investigation tolerance a receiver operator characteristic (ROC) curve anal-
ysis was performed. ROC analysis is generally used to determine the optimal sensitivity and
specificity of a test and to quantify the efficiency of the test [71]–[73]. ROC analysis can there-
fore be used to find the optimal intervention tolerance for EPIgray in order to more optimally
classify passing and failing fields. ROC analysis considers the true positive rate (TPR), given in
equation 5.9 and false positive rate (FPR), given in equation 5.10.
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TPR = Sensitivity
=
Fields correctly classified as passes (TP)
Fields correctly classified as passes (TP) + Fields incorrectly classified as fails (FF)
(5.9)
FPR = 1− Specificity
= 1− Fields incorrectly classified as passing (FP)
Fields incorrectly classified as passing (FP) + Fields correctly classified as fails (TF)
(5.10)
The 255 fields of the retrospective study were used to calculate the TPR and FPR for EPIgray in-
tervention tolerances ranging from±0.5% to±5.0% in 0.5% increments. The resulting TPR and
FPR are shown in table 5.12. Table 5.12 also presents the Youden’s index, which was calculated
using equation 5.11.
TABLE 5.12: ROC Analysis of Proposed EPIgray Intervention Tolerances
Intervention Tol. FPR (%) TPR (%) Youden’s Index
±0.5% 7.1 8.8 0.0
±1.0% 10.7 19.8 0.1
±1.5% 17.2 31.4 0.1
±2.0% 21.4 41.0 0.2
±2.5% 28.6 53.3 0.2
±3.0% 29.6 60.0 0.3
±3.5% 42.9 79.0 0.4
±4.0% 57.1 81.9 0.2
±4.5% 63.1 87.7 0.3
±5.0% 75.0 91.6 0.2
Youden’s Index = Sensitivity + Specificity− 1 (5.11)
Youden’s index provides a method for obtaining the optimal cut off value, in this example it is
the optimal EPIgray intervention tolerance. The maximum Youden’s index value corresponds
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to the optimal EPIgray intervention tolerance [74], [75]. According to table 5.12, this tolerance
is ±3.5%. Figure 5.8 graphically shows the data of table 5.12. The dotted line in Figure 5.8 indi-
cates a one-to-one relationship between the FPR and TPR. That is, the true positive rate equals
the false positive rate, where the true positive rate indicates that all passing fields are correctly
identified however all failing fields are incorrectly considered passing fields. The maximum
distance between the ROC curve and the dashed line indicates the most optimal sensitivity
and specificity. This distance is found to be the greatest for a tolerance of ±3.5%. This obser-
vation is in agreement with the Youden index analysis which also indicated the tolerance of
±3.5% to be the most optimal tolerance for identification of the falsely passing fields.
FIGURE 5.8: ROC curve of investigation tolerances
The area under the curve (AUC) was also analysed to assess accuracy of the ROC test. The AUC
of the ROC curve was found to be 0.72. Greiner et al. have proposed the following categories
to assess the accuracy of the AUC [71]:
• AUC = 0.5 indicates a non-informative test,
• 0.5 < AUC ≤ 0.7 indicates less accurate test,
• 0.7 < AUC ≤ 0.9 indicates moderately accurate test,
• 0.9 < AUC ≤ 1.0 indicates highly accurate test,
• AUC = 1.0 perfect test.
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An AUC of 0.72 indicates a moderately accurate test, and therefore we can reliably use this
tolerance as an intervention tolerance given that there are sufficient clinical resources. The
combined error calculation indicated EPIgray to have an uncertainty of at least ±3.3%. The
ROC analysis has indicated an optimal intervention tolerance of ±3.5%. These tolerances are
sufficiently close to one another however, the ROC indicated tolerance would be considered
more reliable as the combined error calculation is predicting the accuracy of EPIgray doses
for the best case scenario. Therefore from these results, an intervention tolerance of ±3.5% is
proposed. The feasibility of the new intervention tolerance was tested on the 255 fields of the
retrospective study. The results of the investigation are shown in table 5.13.






True Pass 208 (81.6%) 174 (68.2%)
True Fail 7 (2.7%) 16 (6.3%)
False Pass 21 (8.2%) 6 (2.4%)
False Fail 19 (7.5%) 59 (23.1%)
Results of table 5.11 reveal that with the proposed intervention tolerance, the number of truly
passing and falsely passing fields decreased and the number of truly failing and falsely failing
fields increased. These results are consistent with expectations. With a decrease in the inter-
vention tolerance, the fields that have %DDDRP between ±3.5% and ±5.0% before positional
correction are now considered failing results. This reasoning provides an explanation for the
decrease in the number of true passes and an increase in the number of false fails with the im-
plementation of the new tolerances.
Table 5.13 shows the number of true fails to increase and the number of false passes to decrease
with the implementation of the new tolerance. The falsely passing fields will have %DDDRP be-
tween ±3.5% and ±5.0% before positional correction and have a %DDDRP that exceeds ±5.0%
following positional correction. One of the primary purposes of this study was to enable
EPIgray tolerances to be more sensitive in order to identify falsely passing fields. Therefore
the decrease in the intervention tolerance restricts those falsely passing fields with %DDDRP
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between ±3.5% and ±5.0% before positional correction from passing. This consequently de-
creases the number of falsely passing fields and increases the number of truly failing fields.
Evidence from this investigation shows that the decrease in the intervention tolerance resulted
in increased EPIgray sensitivity for detection of falsely passing results.
In considering the most optimal tolerance for the clinic, the intervention rates of the tolerances
should also be considered. With the implementation of the ±3.5% intervention tolerance, the
intervention rate (manual investigation of all failing fields) increases to 10.2% and 29.4%. The
implementation of the new tolerance results in the reduction of false passes from 8.2% to 2.4%.
These results indicate that intervention is required for approximately 30% of the fields how-
ever the significant decrease in the number of false passes with the new tolerance justifies its
implementation. The new intervention tolerance will enable effective identification of fields
that have falsely passed and thereby increase the robustness of the EPIgray IVD system.
5.8 Conclusion
This chapter considered numerous errors contributing to the uncertainty associated with the
EPIgray reconstructed doses. These factors included treatment-related parameters that are
variable from patient to patient, on-treatment setup errors within an acceptable tolerance, in-
herent EPIgray errors and lastly operator-related errors associated with correctional matching
on EPIgray.
The results of this investigation indicated that the current acceptable tolerance is appropriate
as fields beyond the ±5.0% are still accepted as being dosimetrically accurate in certain situa-
tions. However this current tolerance has a significant number of falsely passing fields that go
unnoticed. With this consideration a proposal of ±3.5% intervention tolerance was made. By
employing a smaller intervention tolerance, the number of initially failing fields will increase
the intervention rate however, the number of false passes are significantly reduced. The un-
certainties investigation considered treatment parameters and setup errors specific to 3DCRT




The use of EPIgray for IVD has numerous benefits. An EPID-based IVD system such as EPIgray
provides confirmation that the treatment was delivered as expected with improved time effi-
ciency than other currently used in-vivo dosimeters as additional setup is not required. There
are however limitations in the accuracy of the EPIgray reconstructed doses as a result of the na-
ture of radiotherapy treatments. The use of EPIgray for IVD of 3DCRT breast treatments was
investigated in this study taking into consideration the inaccuracies associated with the treat-
ment parameters as well as the innate uncertainties associated with EPIgray itself. In order to
reliably use EPIgray, this study was designed to optimise the use of EPIgray for IVD of 3DCRT
breast treatments.
This study addressed the aims discussed in Chapter 2 in three parts:
1. The retrospective study,
2. The phantom study,
3. Uncertainties associated with EPIgray reconstructed doses.
In order to achieve the first aim of identifying specific groups of patients at risk of having
positional offsets on treatment using EPIgray, previously treated 3DCRT breast patients who
have had EPID images acquired on treatment were categorised into groups according to breast
size and laterality. These patients were retrospectively analysed within EPIgray as part of a
retrospective study presented in Chapter 3. The results of this part of the study revealed that
patient setup errors in the anterior-posterior direction and the proximal-distal directions were
more common than superior-inferior direction across all breast groups. Positional correction
within EPIgray revealed that right breast patients were more at risk of having errors associated
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with positional setup when considering treatment laterality and large breast patients were at
increased risk of having positional offset on treatment when considering breast size. The ret-
rospective study also examined the effects of positional correction accounting for patient setup
errors on the %DDDRP provided by EPIgray. It was found that EPIgray showed no bias be-
tween breast laterality or size in its dose calculation. The retrospective study results provided
clinical evidence that there is a linear one-to-one relationship between the TPS dose and the
EPIgray reconstructed dose. Evidence in literature revealed that inaccuracies associated with
EPIgray results increased in regions with highly varying tissues densities. The position of
the DRP varies from patient to patient and consequently the proximity of the DRP (located in
breast tissue) to the lower density lung tissue may affect the accuracy of the EPIgray recon-
structed dose. The position of the DRP with reference to the distance from lung tissue was
investigated to determine its suitability of use. The results of this investigation revealed that
the position of the DRP over a range of patients had no significant impact on the accuracy of
the EPIgray reconstructed dose. Aim three of Chapter 2 was to identify more optimal points
in treatment verification analysis. However results have revealed that the current practice of
using DRP dose for treatment verification is not impacted by the varying tissue densities in the
reconstruction window. Despite this finding, the results of the retrospective study has found
false passes are present across all breast groups. With the recent upgrade of EPIgray, DOSIsoft
now recommends the use of %DDvol in place of %DDDRP. The suitability of %DDvol was in-
vestigated using patient data in retrospective analysis. Results of this investigation revealed a
systematic offset between %DDvol and %DDDRP. This part of the study provided evidence that
the use of %DDDRP in combination with %DDvol may aid in the reduction of false passes.
The phantom study presented in Chapter 4 employed a breast-lung phantom specifically de-
signed to isolate the setup error on treatment in terms of direction and the effects of these errors
on the reconstructed dose were examined. Additionally, while the retrospective study found
good agreement between TPS planned dose and EPIgray reconstructed dose, an independent
validation that the reconstructed dose is indicative of the delivered dose was required. There-
fore the breast-lung phantom was designed to incorporate two other established dosimeters for
verification of EPIgray reconstructed dose with positional setup errors. The results of this sec-
tion of the phantom study has revealed that EPIgray reconstructed doses were consistent with
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the doses provided by the IC and film across all positional setup errors. However the EPIgray
doses do present a systematic offset and higher uncertainty. Whilst the accuracy of EPIgray
is offset from other dosimeters, this offset can be incorporated in the clinical tolerance. The
agreement between %DDDRP and %DDvol with setup errors was investigated in the phantom.
Results indicated that %DDvol consistently provided a %DD that indicated a larger deviation
from the TPS dose than that of %DDDRP. The retrospective study results in conjunction with
the phantom study results indicated that a fractional clinical tolerance of ±5.0% placed on
the %DDvol with an standard deviation of less than 0.1 Gy would aid in the reduction of false
passes. In situations where the standard deviation is greater than 0.1 Gy or the±5.0% tolerance
on %DDvol has been exceeded, individual beam analysis should be performed using the DRP
method following positional correction. The phantom study achieved aim four of Chapter 2 by
verifying EPIgray’s ability detect positional setup errors through discrepancies seen between
the TPS dose and the delivered dose.
Lastly, uncertainty analysis was conducted to address the major sources of inaccuracy associ-
ated with the EPIgray reconstructed doses. Errors associated with variations in treatment plan
parameters, setup on treatment, EPIgray uncertainties and operator judgement in positional
corrections were considered. The contributing factors were summed in quadrature according
to GUM methodology for uncorrelated errors to find a total combined error of ±3.3% [70]. The
results of the retrospective study indicated the±5.0% dosimetric tolerance to be appropriate for
3DCRT breast treatments however false passes were still evident. Consequently a new inter-
vention tolerance was proposed and tested. ROC analysis has revealed±3.5% to be the optimal
intervention tolerance for minimising the number of false passes whilst considering clinical
resource availability. Findings of this part of the study indicated that the new intervention
tolerance increases the intervention rate. However the new intervention tolerance significantly
decreases the number of falsely passing fields. The uncertainty analysis and ROC analysis have
indicated tolerances with minor differences. The uncertainty analysis has provided the toler-
ance of the best case scenario and therefore the ROC analysis provided intervention tolerance is
recommended for clinical use. Whilst the second aim of the Chapter 2 of decreasing the ±5.0%
tolerance on the %DDDRP was not directly achieved in that the dosimetric tolerance was not
reduced, the purpose for which this aim was proposed for was met.
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In conclusion, all the aims set at the commencement of this project were achieved. Right breast
and large breast patients were found to be more at risk of having setup errors on treatment.
The current intervention tolerance set for the %DDDRP for 3DCRT breast patients was recom-
mended to be reduced from ±5.0% to ±3.5%. Further reduction of this tolerance for small and
left breast fields is not recommended as this value was based on ROC and uncertainty analysis.
While more optimal points were not investigated following the recognition of the primary rel-
evance of the DRP, alternative dosimetric analysis within EPIgray was investigated using the
%DDvol method recommended by DOSIsoft. A new %DDvol tolerance of ±5.0% is proposed
with a standard deviation tolerance of ±0.1 Gy. Lastly, a breast-lung phantom was used to
verify the ability of EPIgray to detect the discrepancies between the TPS calculated dose and
the delivered dose.
6.2 Future Work
The discrepancies in setup error directions between left and right breast fields were not ex-
pected and currently remains inconclusive. Potential causes of this discrepancy were discussed
in Chapter 3. One of the potential causes discussed included variations in the arm positions of
the patient. For future patients, confirmed consistency in arm positions will allow determina-
tion of whether this cause might be producing the discrepancies seen in the setup of patients
of both lateralities.
Results of this project have also indicated that it would be useful to establish site specific
EPIgray tolerances for other treatment sites treated using the 3DCRT technique. This project
has revealed that false results are likely across a range of patients as a result of having a wide
clinical tolerance of ±5.0% therefore it will be beneficial to perform a similar study for other
treatment sites.
This project considered patients who were treated with a 6 MV photon beam. 6 MV photon
beam is lowest energy photon beam available at Christchurch Hospital and is the most com-
monly used energy for 3DCRT breast treatments. Other photon energies available for treatment
are 10 MV and 15 MV. However these energies are extremely uncommon. EPID information
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from patients treated with higher energies were not available at the commencement of the
retrospective study. Therefore the higher energies were not considered in this project. It is
commonly known that the quality of an EPID image is diminished with increasing energy of
the radiation beam and therefore the effects of radiation energy on the EPIgray reconstructed
doses and accuracy would also be an interesting aspect to explore [76].
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A EPIgray Correctional Analysis
Instructions
A.1 Introduction
EPIgray allows two forms of panel position correction:
1. Panel offset correction figure A.1 – Allows alignment of the field edges from the TPS to
the EPID image acquired on treatment.
2. Contour matching correction figure A.2 – Allows the alignment the planning CT breast
contour from the TPS to the breast contour evident in the EPID image.
FIGURE A.1: a. Misalignment evident between field edges and EPID image. b. Field
edges and EPID image aligned following panel offset correction
A.2 Purpose
Both correctional methods requires judgement of the analyser to find the best alignment. The
purpose of this exercise is to determine the inter-person variability in aligning the field edges
and planning CT breast contour to the EPID images acquired on treatment.
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FIGURE A.2: a. Misalignment between planning CT breast contour and breast contour
on EPID image. b. Alignment of patient breast contour and EPID image breast contour
following contour matching correction.
A.3 Outline
Three existing 3DCRT breast patients (of different breast sizes) in our EPIgray database have
been selected for this exercise. Please perform panel offset correction and contour matching
correction and record the collimator axis position and the relative deviation before and after
correction for all beams and fractions of the selected patients. Please also note in the comments
section:
• Any difficulties faced during alignment using both correction methods,
• any reasons for choosing a panel position when perfect alignment was unattainable.
• If the initial panel position corresponds to good alignment in the panel offset correction
method and/or the contour matching correction method and therefore no correction of
the panel position was necessary.
A.4 Instructions
1. Open EPIgray by double clicking EPIgray Expert on the EPIgray computer desktop.
2. Find and select patient NHI under patient records→ Under studies, right click Ballistic
and select Start a dosimetric verification study. See figure A.3.
3. Enter user name and password.
4. Select EPIgray (target symbol) on the top left hand side of the EPIgray window.
5. Select the drop down arrow next to Follow-up: Ballistic to view beams grouped together
from three fractions.
A.4. Instructions 131
6. In the summary for each beam figure A.4, check that the initial relative deviation matches
the corresponding value in table A.1 and record this value in the provided Excel Spread-
sheet. If this value differs please let me know before performing any corrections.
7. Select a particular beam of a given fraction and press the centering symbol to begin
matching (figure A.5).
• The centering button will enable the field edges to be visible.
• Record the collimator axis x and y positions in the Excel Spreadsheet. (Again check
these initial collimator axis positions are identical to the values given in table 1 before
proceeding).
• Press the lock button to unlock the current collimator axis position to allow correc-
tions to be made.
8. Matching could be performed manually by typing in the collimator axis co-ordinates in x
and y directions OR by hovering over the crosshairs of the red dotted line and dragging
the purple box.
9. First perform panel offset matching (in the top left hand window): matching field edges
(purple box) to the EPID image. Note. You can adjust the window and level of the EPID
image to aid alignment.
10. Once happy with alignment, press Apply. The collimator lock icon should now be in a
closed state. Record the collimator axis x and y positions in the appropriate column only
after applying the shift.
11. Select overall beam summary (of all 3 fractions) and record the relative deviation of the
beam and the fraction you’ve just adjusted.
12. Return to the same fraction of the beam you were previously adjusting and perform the
matching of the breast contour and the EPID image. Perform steps 10 – 11.
13. Perform these steps 6 – 12 for all beams and fractions for all three patients patients.
14. Once you have finished correction of each fraction of each beam for a given patient. Press
the close icon on the top right hand side of the screen.
• You will be asked if you want to save the changes made.
• Select quit without saving.
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